Hubbry Logo
search
logo
Virus
Virus
current hub
1219961

Virus

logo
Community Hub0 Subscribers
Read side by side
from Wikipedia

Virus
"Severe acute respiratory syndrome coronavirus 2"
SARS-CoV-2, a member of the subfamily Orthocoronavirinae
Virus classification Edit this classification
(unranked): Virus
Realms

A virus is a submicroscopic infectious agent that replicates only inside the living cells of an organism.[1] Viruses infect all life forms, from animals and plants to microorganisms, including bacteria and archaea.[2][3] Viruses are found in almost every ecosystem on Earth and are the most numerous type of biological entity.[4][5] Since Dmitri Ivanovsky's 1892 article describing a non-bacterial pathogen infecting tobacco plants and the discovery of the tobacco mosaic virus by Martinus Beijerinck in 1898,[6]: 4  more than 16,000 of the millions of virus species have been described in detail.[7][8] The study of viruses is known as virology, a subspeciality of microbiology.

When infected, a host cell is often forced to rapidly produce thousands of copies of the original virus. When not inside an infected cell or in the process of infecting a cell, viruses exist in the form of independent viral particles, or virions, consisting of (i) genetic material, i.e., long molecules of DNA or RNA that encode the structure of the proteins by which the virus acts; (ii) a protein coat, the capsid, which surrounds and protects the genetic material; and in some cases (iii) an outside envelope of lipids. The shapes of these virus particles range from simple helical and icosahedral forms to more complex structures. Most virus species have virions too small to be seen with an optical microscope and are one-hundredth the size of most bacteria.

The origins of viruses in the evolutionary history of life are still unclear. Some viruses may have evolved from plasmids, which are pieces of DNA that can move between cells. Other viruses may have evolved from bacteria. In evolution, viruses are an important means of horizontal gene transfer, which increases genetic diversity in a way analogous to sexual reproduction.[9] Viruses are considered by some biologists to be a life form, because they carry genetic material, reproduce, and evolve through natural selection, although they lack some key characteristics, such as cell structure, that are generally considered necessary criteria for defining life. Because they possess some but not all such qualities, viruses have been described as "organisms at the edge of life"[10] and as replicators.[11]

Viruses spread in many ways. One transmission pathway is through disease-bearing organisms known as vectors: for example, viruses are often transmitted from plant to plant by insects that feed on plant sap, such as aphids; and viruses in animals can be carried by blood-sucking insects. Many viruses spread in the air by coughing and sneezing, including influenza viruses, SARS-CoV-2, chickenpox, smallpox, and measles. Norovirus and rotavirus, common causes of viral gastroenteritis, are transmitted by the faecal–oral route, passed by hand-to-mouth contact or in food or water. The infectious dose of norovirus required to produce infection in humans is fewer than 100 particles.[12] HIV is one of several viruses transmitted through sexual contact and by exposure to infected blood. The variety of host cells that a virus can infect is called its host range: this is narrow for viruses specialized to infect only a few species, or broad for viruses capable of infecting many.[13]: 123–124 

Viral infections in animals provoke an immune response that usually eliminates the infecting virus. Immune responses can also be produced by vaccines, which confer an artificially acquired immunity to the specific viral infection. Some viruses, including those that cause HIV/AIDS, HPV infection, and viral hepatitis, evade these immune responses and result in chronic infections. Several classes of antiviral drugs have been developed.

Etymology

[edit]

The English word "virus" comes from the Latin word vīrus, which refers to poison and other noxious liquids. Vīrus comes from the same Indo-European root as Sanskrit viṣa, Avestan vīša, and Ancient Greek ἰός (iós), which all mean "poison". The first attested use of "virus" in English appeared in 1398 in John Trevisa's translation of Bartholomeus Anglicus's De Proprietatibus Rerum.[14][15] Virulent, from Latin virulentus ('poisonous'), dates to c. 1400.[16][17] A meaning of 'agent that causes infectious disease' is first recorded in 1728,[15] long before the discovery of viruses by Dmitri Ivanovsky in 1892. The English plural is viruses (sometimes also vira),[18] whereas the Latin word is a mass noun, which has no classically attested plural (vīra is used in Neo-Latin[19]). The adjective viral dates to 1948.[20] The term virion (plural virions), which dates from 1959,[21] is also used to refer to a single viral particle that is released from the cell and is capable of infecting other cells of the same type.[22]

Origins

[edit]

Viruses are found wherever there is life and have probably existed since living cells first evolved.[23] The origin of viruses is unclear because they do not form fossils, so molecular techniques are used to infer how they arose.[24] In addition, viral genetic material occasionally integrates into the germline of the host organisms, by which they can be passed on vertically to the offspring of the host for many generations. This provides an invaluable source of information for paleovirologists to trace back ancient viruses that existed as far back as millions of years ago.

There are three main hypotheses that aim to explain the origins of viruses:[25]

Regressive hypothesis
Viruses may have once been small cells that parasitised larger cells. Over time, genes not required by their parasitism were lost. The bacteria rickettsia and chlamydia are living cells that, like viruses, can reproduce only inside host cells. They lend support to this hypothesis, as their dependence on parasitism is likely to have caused the loss of genes that enabled them to survive outside a cell. This is also called the "degeneracy hypothesis",[6]: 16 [26]: 11  or "reduction hypothesis".[27]: 24 
Cellular origin hypothesis
Some viruses may have evolved from bits of DNA or RNA that "escaped" from the genes of a larger organism. The escaped DNA could have come from plasmids (pieces of naked DNA that can move between cells) or transposons (molecules of DNA that replicate and move around to different positions within the genes of the cell).[13]: 810  Once called "jumping genes", transposons are examples of mobile genetic elements and could be the origin of some viruses. They were discovered in maize by Barbara McClintock in 1950.[28] This is sometimes called the "vagrancy hypothesis",[6]: 16 [26]: 11–12  or the "escape hypothesis".[27]: 24 
Co-evolution hypothesis
This is also called the "virus-first hypothesis"[27]: 24  and proposes that viruses may have evolved from complex molecules of protein and nucleic acid at the same time that cells first appeared on Earth and would have been dependent on cellular life for billions of years. Viroids are molecules of RNA that are not classified as viruses because they lack a protein coat. They have characteristics that are common to several viruses and are often called subviral agents.[6]: 55  Viroids are significant pathogens of plants.[13]: 791  They do not code for proteins but interact with the host cell and use the host machinery for their replication.[29] The hepatitis delta virus of humans has an RNA genome similar to viroids but has a protein coat derived from hepatitis B virus and cannot produce one of its own. It is, therefore, a defective virus. Although hepatitis delta virus genome may replicate independently once inside a host cell, it requires the help of hepatitis B virus to provide a protein coat so that it can be transmitted to new cells.[13]: 460  In similar manner, the sputnik virophage is dependent on mimivirus, which infects the protozoan Acanthamoeba castellanii.[30] These viruses, which are dependent on the presence of other virus species in the host cell, are called "satellites" and may represent evolutionary intermediates of viroids and viruses.[26]: 777 [6]: 55–57 

In the past, there were problems with all of these hypotheses: the regressive hypothesis did not explain why even the smallest of cellular parasites do not resemble viruses in any way. The escape hypothesis did not explain the complex capsids and other structures on virus particles. The virus-first hypothesis contravened the definition of viruses in that they require host cells.[27]: 24  Viruses are now recognised as ancient and as having origins that pre-date the divergence of life into the three domains.[27]: 28  This discovery has led modern virologists to reconsider and re-evaluate these three classical hypotheses.[27]: 28 

The evidence for an ancestral world of RNA cells[27]: 26  and computer analysis of viral and host DNA sequences give a better understanding of the evolutionary relationships between different viruses and may help identify the ancestors of modern viruses. To date, such analyses have not proved which of these hypotheses is correct.[27]: 26  It seems unlikely that all currently known viruses have a common ancestor, and viruses have probably arisen numerous times in the past by one or more mechanisms.[31]

Microbiology

[edit]

Discovery

[edit]

The first evidence of the existence of viruses came from experiments with filters that had pores small enough to retain bacteria. In 1892, Dmitri Ivanovsky used one of these filters to show that sap from a diseased tobacco plant remained infectious to healthy tobacco plants despite having been filtered. Martinus Beijerinck called the filtered, infectious substance a "virus" and this discovery is considered to be the beginning of virology. The subsequent discovery and partial characterization of bacteriophages by Frederick Twort and Félix d'Herelle further catalyzed the field, and by the early 20th century many viruses had been discovered. In 1926, Thomas Milton Rivers defined viruses as obligate parasites. Viruses were demonstrated to be particles, rather than a fluid, by Wendell Meredith Stanley, and the invention of the electron microscope in 1931 allowed their complex structures to be visualised.[32]

Life properties

[edit]

Scientific opinions differ on whether viruses are a form of life or organic structures that interact with living organisms.[11] They have been described as "organisms at the edge of life",[10] since they resemble organisms in that they possess genes, evolve by natural selection,[33] and reproduce by creating multiple copies of themselves through self-assembly. Although they have genes, they do not have a cellular structure, which is often seen as the basic unit of life. Viruses do not have their own metabolism and require a host cell to make new products. They therefore cannot naturally reproduce outside a host cell[34]—although some bacteria such as rickettsia and chlamydia are considered living organisms despite the same limitation.[35][36] Accepted forms of life use cell division to reproduce, whereas viruses spontaneously assemble within cells. They differ from autonomous growth of crystals as they inherit genetic mutations while being subject to natural selection. Virus self-assembly within host cells has implications for the study of the origin of life, as it lends further credence to the hypothesis that life could have started as self-assembling organic molecules.[2] The virocell model first proposed by Patrick Forterre considers the infected cell to be the "living form" of viruses and that virus particles (virions) are analogous to spores.[37] Although the living versus non-living debate continues, the virocell model has gained some acceptance.[38]

Structure

[edit]
Virions of some of the most common human viruses with their relative size. The nucleic acids are not to scale.
Diagram of how a virus capsid can be constructed using multiple copies of just two protein molecules
Structure of tobacco mosaic virus: RNA coiled in a helix of repeating protein sub-units
Structure of icosahedral adenovirus. Electron micrograph with an illustration to show shape
Structure of chickenpox virus. They have a lipid envelope.
Structure of an icosahedral cowpea mosaic virus
Bacteriophage Escherichia virus MS2 capsid. This spherical virus also has icosahedral symmetry.

Viruses display a wide diversity of sizes and shapes, called 'morphologies'. In general, viruses are much smaller than bacteria and more than a thousand bacteriophage viruses would fit inside an Escherichia coli bacterium's cell.[39]: 98  Many viruses that have been studied are spherical and have a diameter between 20 and 300 nanometres. Some filoviruses, which are filaments, have a total length of up to 1400 nm; their diameters are only about 80 nm.[26]: 33–55  Most viruses cannot be seen with an optical microscope, so scanning and transmission electron microscopes are used to visualise them.[26]: 33–37  To increase the contrast between viruses and the background, electron-dense "stains" are used. These are solutions of salts of heavy metals, such as tungsten, that scatter the electrons from regions covered with the stain. When virions are coated with stain (positive staining), fine detail is obscured. Negative staining overcomes this problem by staining the background only.[40]

A complete virus particle, known as a virion, consists of nucleic acid surrounded by a protective coat of protein called a capsid. These are formed from protein subunits called capsomeres.[26]: 40  Viruses can have a lipid "envelope" derived from the host cell membrane. The capsid is made from proteins encoded by the viral genome and its shape serves as the basis for morphological distinction.[41][42] Virally-coded protein subunits will self-assemble to form a capsid, in general requiring the presence of the virus genome. Complex viruses code for proteins that assist in the construction of their capsid. Proteins associated with nucleic acid are known as nucleoproteins, and the association of viral capsid proteins with viral nucleic acid is called a nucleocapsid. The capsid and entire virus structure can be mechanically (physically) probed through atomic force microscopy.[43][44] In general, there are five main morphological virus types:

Helical
These viruses are composed of a single type of capsomere stacked around a central axis to form a helical structure, which may have a central cavity, or tube. This arrangement results in virions which can be short and highly rigid rods, or long and very flexible filaments. The genetic material (typically single-stranded RNA, but single-stranded DNA in some cases) is bound into the protein helix by interactions between the negatively charged nucleic acid and positive charges on the protein. Overall, the length of a helical capsid is related to the length of the nucleic acid contained within it, and the diameter is dependent on the size and arrangement of capsomeres. The well-studied tobacco mosaic virus[26]: 37 and inovirus[45] are examples of helical viruses.
Icosahedral
Most animal viruses are icosahedral or near-spherical with chiral icosahedral symmetry. A regular icosahedron is the optimum way of forming a closed shell from identical subunits. The minimum number of capsomeres required for each triangular face is 3, which gives 60 for the icosahedron. Many viruses, such as rotavirus, have more than 60 capsomers and appear spherical but they retain this symmetry. To achieve this, the capsomeres at the apices are surrounded by five other capsomeres and are called pentons. Capsomeres on the triangular faces are surrounded by six others and are called hexons.[26]: 40, 42  Hexons are in essence flat and pentons, which form the 12 vertices, are curved. The same protein may act as the subunit of both the pentamers and hexamers or they may be composed of different proteins.[46]
Prolate
This is an icosahedron elongated along the fivefold axis and is a common arrangement of the heads of bacteriophages. This structure is composed of a cylinder with a cap at either end.[47]
Enveloped
Some species of virus envelop themselves in a modified form of one of the cell membranes, either the outer membrane surrounding an infected host cell or internal membranes such as a nuclear membrane or endoplasmic reticulum, thus gaining an outer lipid bilayer known as a viral envelope. This membrane is studded with proteins coded for by the viral genome and host genome; the lipid membrane itself and any carbohydrates present originate entirely from the host. Influenza virus, HIV (which causes AIDS), and severe acute respiratory syndrome coronavirus 2 (which causes COVID-19)[48] use this strategy. Most enveloped viruses are dependent on the envelope for their infectivity.[26]: 42–43 
Complex
These viruses possess a capsid that is neither purely helical nor purely icosahedral, and that may possess extra structures such as protein tails or a complex outer wall. Some bacteriophages, such as Enterobacteria phage T4, have a complex structure consisting of an icosahedral head bound to a helical tail, which may have a hexagonal base plate with protruding protein tail fibres. This tail structure acts like a molecular syringe, attaching to the bacterial host and then injecting the viral genome into the cell.[49]

The poxviruses are large, complex viruses that have an unusual morphology. The viral genome is associated with proteins within a central disc structure known as a nucleoid. The nucleoid is surrounded by a membrane and two lateral bodies of unknown function. The virus has an outer envelope with a thick layer of protein studded over its surface. The whole virion is slightly pleomorphic, ranging from ovoid to brick-shaped.[50]

Giant viruses

[edit]

Mimivirus is one of the largest characterised viruses, with a capsid diameter of 400 nm. Protein filaments measuring 100 nm project from the surface. The capsid appears hexagonal under an electron microscope, therefore the capsid is probably icosahedral.[51] In 2011, researchers discovered the largest then known virus in samples of water collected from the ocean floor off the coast of Las Cruces, Chile. Provisionally named Megavirus chilensis, it can be seen with a basic optical microscope.[52] In 2013, the Pandoravirus genus was discovered in Chile and Australia, and has genomes about twice as large as Megavirus and Mimivirus.[53] All giant viruses have dsDNA genomes and they are classified into several families: Mimiviridae, Pithoviridae, Pandoraviridae, Phycodnaviridae, and the Mollivirus genus.[54]

Some viruses that infect Archaea have complex structures unrelated to any other form of virus, with a wide variety of unusual shapes, ranging from spindle-shaped structures to viruses that resemble hooked rods, teardrops or even bottles. Other archaeal viruses resemble the tailed bacteriophages, and can have multiple tail structures.[55]

Genome

[edit]
Genomic diversity among viruses
Property Parameters
Nucleic acid
  • DNA
  • RNA
  • Both DNA and RNA (one or the other at different stages in the life cycle)
Shape
  • Linear
  • Circular
  • Segmented
Strandedness
  • Single-stranded (ss)
  • Double-stranded (ds)
  • Double-stranded with regions of single-strandedness
Sense
  • Positive sense (+)
  • Negative sense (−)
  • Ambisense (+/−)

An enormous variety of genomic structures can be seen among viral species; as a group, they contain more structural genomic diversity than plants, animals, archaea, or bacteria. There are millions of different types of viruses,[8] although fewer than 7,000 types have been described in detail.[6]: 49  As of January 2021, the NCBI Virus genome database has more than 193,000 complete genome sequences,[56] but there are doubtlessly many more to be discovered.[57][58]

A virus has either a DNA or an RNA genome and is called a DNA virus or an RNA virus, respectively. Some RNA viruses, for example retroviruses, have a stage in their replication cycle where the genome is encoded in DNA.[59] Most viruses have RNA genomes. Plant viruses tend to have single-stranded RNA genomes and bacteriophages tend to have double-stranded DNA genomes.[26]: 96–99 

Viral genomes are circular, as in the polyomaviruses, or linear, as in the adenoviruses. The type of nucleic acid is irrelevant to the shape of the genome. Among RNA viruses and certain DNA viruses, the genome is often divided into separate parts, in which case it is called segmented. For RNA viruses, each segment often codes for only one protein and they are usually found together in one capsid. All segments are not required to be in the same virion for the virus to be infectious, as demonstrated by brome mosaic virus and several other plant viruses.[26]: 33–35 

A viral genome, irrespective of nucleic acid type, is almost always either single-stranded (ss) or double-stranded (ds). Single-stranded genomes consist of an unpaired nucleic acid, analogous to one-half of a ladder split down the middle. Double-stranded genomes consist of two complementary paired nucleic acids, analogous to a ladder. The virus particles of some virus families, such as those belonging to the Hepadnaviridae, contain a genome that is partially double-stranded and partially single-stranded.[26]: 96–99 

For most viruses with RNA genomes and some with single-stranded DNA (ssDNA) genomes, the single strands are said to be either positive-sense (called the 'plus-strand') or negative-sense (called the 'minus-strand'), depending on if they are complementary to the viral messenger RNA (mRNA). Positive-sense viral RNA is in the same sense as viral mRNA and thus at least a part of it can be immediately translated by the host cell. Negative-sense viral RNA is complementary to mRNA and thus must be converted to positive-sense RNA by an RNA-dependent RNA polymerase before translation. DNA nomenclature for viruses with genomic ssDNA is similar to RNA nomenclature, in that positive-strand viral ssDNA is identical in sequence to the viral mRNA and is thus a coding strand, while negative-sense viral ssDNA is complementary to the viral mRNA and is thus a template strand.[26]: 96–99  Several types of ssDNA and ssRNA viruses have genomes that are ambisense in that transcription can occur off both strands in a double-stranded replicative intermediate. Examples include geminiviruses, which are ssDNA plant viruses and arenaviruses, which are ssRNA viruses of animals.[60]

Genome size

[edit]

Genome size varies greatly between species. The smallest—the ssDNA circoviruses, family Circoviridae—code for only two proteins and have a genome size of only two kilobases;[61] the largest—the pandoraviruses—have genome sizes of around two megabases which code for about 2500 proteins.[53] Virus genes rarely have introns and often are arranged in the genome so that they overlap.[62]

In general, RNA viruses have smaller genome sizes than DNA viruses because of a higher error-rate when replicating, and have a maximum upper size limit.[24] Beyond this, errors when replicating render the virus useless or uncompetitive. To compensate, RNA viruses often have segmented genomes—the genome is split into smaller molecules—thus reducing the chance that an error in a single-component genome will incapacitate the entire genome. In contrast, DNA viruses generally have larger genomes because of the high fidelity of their replication enzymes.[63] Single-strand DNA viruses are an exception to this rule, as mutation rates for these genomes can approach the extreme of the ssRNA virus case.[64]

Genetic mutation and recombination

[edit]
Evolution mechanisms of Influenza A virus. (A) Antigenic Drift: Gradual accumulation of mutations in the genome of IAVs leads to emergence of new virus variants. (B) Antigenic Shift: The reassortment of genetic segments between two or more invading IAVs in a host cell can lead to emergence of an antigenically novel subtype.

Viruses undergo genetic change by several mechanisms. These include a process called antigenic drift where individual bases in the DNA or RNA mutate to other bases. Most of these point mutations are "silent"—they do not change the protein that the gene encodes—but others can confer evolutionary advantages such as resistance to antiviral drugs.[65][66] Antigenic shift occurs when there is a major change in the genome of the virus. This can be a result of recombination or reassortment. The Influenza A virus is highly prone to reassortment; occasionally this has resulted in novel strains which have caused pandemics.[67] RNA viruses often exist as quasispecies or swarms of viruses of the same species but with slightly different genome nucleoside sequences. Such quasispecies are a prime target for natural selection.[68]

Segmented genomes confer evolutionary advantages; different strains of a virus with a segmented genome can shuffle and combine genes and produce progeny viruses (or offspring) that have unique characteristics. This is called reassortment or 'viral sex'.[69]

Genetic recombination is a process by which a strand of DNA (or RNA) is broken and then joined to the end of a different DNA (or RNA) molecule. This can occur when viruses infect cells simultaneously and studies of viral evolution have shown that recombination has been rampant in the species studied.[70] Recombination is common to both RNA and DNA viruses.[71][72]

Coronaviruses have a single-strand positive-sense RNA genome. Replication of the genome is catalyzed by an RNA-dependent RNA polymerase. The mechanism of recombination used by coronaviruses likely involves template switching by the polymerase during genome replication.[73] This process appears to be an adaptation for coping with genome damage.[74]

Replication cycle

[edit]
A typical virus replication cycle
Some bacteriophages inject their genomes into bacterial cells (not to scale)

Viral populations do not grow through cell division, because they are acellular. Instead, they use the machinery and metabolism of a host cell to produce multiple copies of themselves, and they assemble in the cell.[75] When infected, the host cell is forced to rapidly produce thousands of copies of the original virus.[76]

Their life cycle differs greatly between species, but there are six basic stages in their life cycle:[26]: 75–91 

Attachment is a specific binding between viral capsid proteins and specific receptors on the host cellular surface. This specificity determines the host range and type of host cell of a virus. For example, HIV infects a limited range of human leucocytes. This is because its surface protein, gp120, specifically interacts with the CD4 molecule—a chemokine receptor—which is most commonly found on the surface of CD4+ T-Cells. This mechanism has evolved to favour those viruses that infect only cells in which they are capable of replication. Attachment to the receptor can induce the viral envelope protein to undergo changes that result in the fusion of viral and cellular membranes, or changes of non-enveloped virus surface proteins that allow the virus to enter.[77]

Penetration or viral entry follows attachment: Virions enter the host cell through receptor-mediated endocytosis or membrane fusion. The infection of plant and fungal cells is different from that of animal cells. Plants have a rigid cell wall made of cellulose, and fungi one of chitin, so most viruses can get inside these cells only after trauma to the cell wall.[6]: 70  Nearly all plant viruses (such as tobacco mosaic virus) can also move directly from cell to cell, in the form of single-stranded nucleoprotein complexes, through pores called plasmodesmata.[78] Bacteria, like plants, have strong cell walls that a virus must breach to infect the cell. Given that bacterial cell walls are much thinner than plant cell walls due to their much smaller size, some viruses have evolved mechanisms that inject their genome into the bacterial cell across the cell wall, while the viral capsid remains outside.[6]: 71 

Uncoating is a process in which the viral capsid is removed: This may be by degradation by viral enzymes or host enzymes or by simple dissociation; the end-result is the releasing of the viral genomic nucleic acid.[79]

Replication of viruses involves primarily multiplication of the genome. Replication involves the synthesis of viral messenger RNA (mRNA) from "early" genes (with exceptions for positive-sense RNA viruses), viral protein synthesis, possible assembly of viral proteins, then viral genome replication mediated by early or regulatory protein expression. This may be followed, for complex viruses with larger genomes, by one or more further rounds of mRNA synthesis: "late" gene expression is, in general, of structural or virion proteins.[80]

Assembly – Following the structure-mediated self-assembly of the virus particles, some modification of the proteins often occurs. In viruses such as HIV, this modification (sometimes called maturation) occurs after the virus has been released from the host cell.[81]

Release – Viruses can be released from the host cell by lysis, a process that kills the cell by bursting its membrane and cell wall if present: this is a feature of many bacterial and some animal viruses. Some viruses undergo a lysogenic cycle where the viral genome is incorporated by genetic recombination into a specific place in the host's chromosome. The viral genome is then known as a "provirus" or, in the case of bacteriophages a "prophage".[13]: 836  Whenever the host divides, the viral genome is also replicated. The viral genome is mostly silent within the host. At some point, the provirus or prophage may give rise to the active virus, which may lyse the host cells.[6]: 243–259  Enveloped viruses (e.g., HIV) typically are released from the host cell by budding. During this process, the virus acquires its envelope, which is a modified piece of the host's plasma or other, internal membrane.[6]: 185–187 

Genome replication

[edit]

The genetic material within virus particles, and the method by which the material is replicated, varies considerably between different types of viruses.

DNA viruses
The genome replication of most DNA viruses takes place in the cell's nucleus. If the cell has the appropriate receptor on its surface, these viruses enter the cell either by direct fusion with the cell membrane (e.g., herpesviruses) or—more usually—by receptor-mediated endocytosis. Most DNA viruses are entirely dependent on the host cell's DNA and RNA synthesising machinery and RNA processing machinery. Viruses with larger genomes may encode much of this machinery themselves. In eukaryotes, the viral genome must cross the cell's nuclear membrane to access this machinery, while in bacteria it need only enter the cell.[13]: 118 [26]: 78 
RNA viruses
Replication of RNA viruses usually takes place in the cytoplasm. RNA viruses can be placed into four different groups depending on their modes of replication. The polarity (whether or not it can be used directly by ribosomes to make proteins) of single-stranded RNA viruses largely determines the replicative mechanism; the other major criterion is whether the genetic material is single-stranded or double-stranded. All RNA viruses use their own RNA replicase enzymes to create copies of their genomes.[26]: 79 
Reverse transcribing viruses
Reverse transcribing viruses have ssRNA (Retroviridae, Metaviridae, Pseudoviridae) or dsDNA (Caulimoviridae, and Hepadnaviridae) in their particles. Reverse transcribing viruses with RNA genomes (retroviruses) use a DNA intermediate to replicate, whereas those with DNA genomes (pararetroviruses) use an RNA intermediate during genome replication. Both types use a reverse transcriptase, or RNA-dependent DNA polymerase enzyme, to carry out the nucleic acid conversion. Retroviruses integrate the DNA produced by reverse transcription into the host genome as a provirus as a part of the replication process; pararetroviruses do not, although integrated genome copies of especially plant pararetroviruses can give rise to infectious virus.[82] They are susceptible to antiviral drugs that inhibit the reverse transcriptase enzyme, e.g. zidovudine and lamivudine. An example of the first type is HIV, which is a retrovirus. Examples of the second type are the Hepadnaviridae, which includes Hepatitis B virus.[26]: 88–89 

Cytopathic effects on the host cell

[edit]

The range of structural and biochemical effects that viruses have on the host cell is extensive.[26]: 115–146  These are called 'cytopathic effects'.[26]: 115  Most virus infections eventually result in the death of the host cell. The causes of death include cell lysis, alterations to the cell's surface membrane and apoptosis.[83] Often cell death is caused by cessation of its normal activities because of suppression by virus-specific proteins, not all of which are components of the virus particle.[84] The distinction between cytopathic and harmless is gradual. Some viruses, such as Epstein–Barr virus, can cause cells to proliferate without causing malignancy,[85] while others, such as papillomaviruses, are established causes of cancer.[86]

Dormant and latent infections

[edit]

Some viruses cause no apparent changes to the infected cell. Cells in which the virus is latent and inactive show few signs of infection and often function normally.[87] This causes persistent infections and the virus is often dormant for many months or years. This is often the case with herpes viruses.[88][89]

Host range

[edit]

Viruses are by far the most abundant biological entities on Earth and they outnumber all the others put together.[90] They infect all types of cellular life including animals, plants, bacteria and fungi.[6]: 49  Different types of viruses can infect only a limited range of hosts and many are species-specific. Some, such as smallpox virus for example, can infect only one species—in this case humans,[13]: 643  and are said to have a narrow host range. Other viruses, such as rabies virus, can infect different species of mammals and are said to have a broad range.[13]: 631  The viruses that infect plants are harmless to animals, and most viruses that infect other animals are harmless to humans.[6]: 272  The host range of some bacteriophages is limited to a single strain of bacteria and they can be used to trace the source of outbreaks of infections by a method called phage typing.[91] The complete set of viruses in an organism or habitat is called the virome; for example, all human viruses constitute the human virome.[92]

Novel viruses

[edit]

A novel virus is one that has not previously been recorded. It can be a virus that is isolated from its natural reservoir or isolated as the result of spread to an animal or human host where the virus had not been identified before. It can be an emergent virus, one that represents a new virus, but it can also be an extant virus that has not been previously identified.[93] The SARS-CoV-2 coronavirus that caused the COVID-19 pandemic is an example of a novel virus.[94]

Classification

[edit]

Classification seeks to describe the diversity of viruses by naming and grouping them on the basis of similarities. In 1962, André Lwoff, Robert Horne, and Paul Tournier were the first to develop a means of virus classification, based on the Linnaean hierarchical system.[95] This system based classification on phylum, class, order, family, genus, and species. Viruses were grouped according to their shared properties (not those of their hosts) and the type of nucleic acid forming their genomes.[96] In 1966, the International Committee on Taxonomy of Viruses (ICTV) was formed. The system proposed by Lwoff, Horne and Tournier was initially not accepted by the ICTV because the small genome size of viruses and their high rate of mutation made it difficult to determine their ancestry beyond order. As such, the Baltimore classification system has come to be used to supplement the more traditional hierarchy.[97] Starting in 2018, the ICTV began to acknowledge deeper evolutionary relationships between viruses that have been discovered over time and adopted a 15-rank classification system ranging from realm to species.[98] Additionally, some species within the same genus are grouped into a genogroup.[99][100]

ICTV classification

[edit]

The ICTV developed the current classification system and wrote guidelines that put a greater weight on certain virus properties to maintain family uniformity. A unified taxonomy (a universal system for classifying viruses) has been established.[101] Only a small part of the total diversity of viruses has been studied.[102] As of 2024, 7 realms, 11 kingdoms, 22 phyla, 4 subphyla, 49 classes, 93 orders, 12 suborders, 368 families, 213 subfamilies, 3,769 genera, 86 subgenera, and 16,215 species of viruses have been defined by the ICTV.[7]

The general taxonomic structure of taxon ranges and the suffixes used in taxonomic names are shown hereafter. As of 2022, the ranks of subrealm, subkingdom, and subclass are unused, whereas all other ranks are in use.[7]

Realm (-viria)
Subrealm (-vira)
Kingdom (-virae)
Subkingdom (-virites)
Phylum (-viricota)
Subphylum (-viricotina)
Class (-viricetes)
Subclass (-viricetidae)
Order (-virales)
Suborder (-virineae)
Family (-viridae)
Subfamily (-virinae)
Genus (-virus)
Subgenus (-virus)
Species

Baltimore classification

[edit]
A diagram showing how the Baltimore Classification is based on a virus's DNA or RNA and method of mRNA synthesis
The Baltimore Classification of viruses is based on the method of viral mRNA synthesis

The Nobel Prize-winning biologist David Baltimore devised the Baltimore classification system.[103][104] The ICTV classification system is used in conjunction with the Baltimore classification system in modern virus classification.[105][106][107]

The Baltimore classification of viruses is based on the mechanism of mRNA production. Viruses must generate mRNAs from their genomes to produce proteins and replicate themselves, but different mechanisms are used to achieve this in each virus family. Viral genomes may be single-stranded (ss) or double-stranded (ds), RNA or DNA, and may or may not use reverse transcriptase (RT). In addition, ssRNA viruses may be either sense (+) or antisense (−). This classification places viruses into seven groups:


Role in human disease

[edit]
A photograph of the upper body of a man labelled with the names of viruses that infect the different parts
Overview of the main types of viral infection and the most notable species involved[108]

Examples of common human diseases caused by viruses include the common cold, influenza, chickenpox, and cold sores. Many serious diseases such as rabies, Ebola virus disease, AIDS (HIV), avian influenza, and SARS are caused by viruses. The relative ability of viruses to cause disease is described in terms of virulence. Other diseases are under investigation to discover if they have a virus as the causative agent, such as the possible connection between human herpesvirus 6 (HHV6) and neurological diseases such as multiple sclerosis and chronic fatigue syndrome.[109] There is controversy over whether the bornavirus, previously thought to cause neurological diseases in horses, could be responsible for psychiatric illnesses in humans.[110]

Viruses have different mechanisms by which they produce disease in an organism, which depends largely on the viral species. Mechanisms at the cellular level primarily include cell lysis, the breaking open and subsequent death of the cell. In multicellular organisms, if enough cells die, the whole organism will start to suffer the effects. Although viruses cause disruption of healthy homeostasis, resulting in disease, they may exist relatively harmlessly within an organism. An example would include the ability of the herpes simplex virus, which causes cold sores, to remain in a dormant state within the human body. This is called latency[111] and is a characteristic of the herpes viruses, including Epstein–Barr virus, which causes glandular fever, and varicella zoster virus, which causes chickenpox and shingles. Most people have been infected with at least one of these types of herpes virus.[112] These latent viruses might sometimes be beneficial, as the presence of the virus can increase immunity against bacterial pathogens, such as Yersinia pestis.[113]

Some viruses can cause lifelong or chronic infections, where the viruses continue to replicate in the body despite the host's defence mechanisms.[114] This is common in hepatitis B virus and hepatitis C virus infections. People chronically infected are known as carriers, as they serve as reservoirs of infectious virus.[115] In populations with a high proportion of carriers, the disease is said to be endemic.[116]

Epidemiology

[edit]

Viral epidemiology is the branch of medical science that deals with the transmission and control of virus infections in humans. Transmission of viruses can be vertical, which means from mother to child, or horizontal, which means from person to person. Examples of vertical transmission include hepatitis B virus and HIV, where the baby is born already infected with the virus.[117] Another, more rare, example is the varicella zoster virus, which, although causing relatively mild infections in children and adults, can be fatal to the foetus and newborn baby.[118]

Horizontal transmission is the most common mechanism of spread of viruses in populations.[119] Horizontal transmission can occur when body fluids are exchanged during sexual activity, by exchange of saliva or when contaminated food or water is ingested. It can also occur when aerosols containing viruses are inhaled or by insect vectors such as when infected mosquitoes penetrate the skin of a host.[119] Most types of viruses are restricted to just one or two of these mechanisms and they are referred to as "respiratory viruses" or "enteric viruses" and so forth. The rate or speed of transmission of viral infections depends on factors that include population density, the number of susceptible individuals, (i.e., those not immune),[120] the quality of healthcare and the weather.[121]

Epidemiology is used to break the chain of infection in populations during outbreaks of viral diseases.[13]: 264  Control measures are used that are based on knowledge of how the virus is transmitted. It is important to find the source, or sources, of the outbreak and to identify the virus. Once the virus has been identified, the chain of transmission can sometimes be broken by vaccines. When vaccines are not available, sanitation and disinfection can be effective. Often, infected people are isolated from the rest of the community, and those that have been exposed to the virus are placed in quarantine.[13]: 894  To control the outbreak of foot-and-mouth disease in cattle in Britain in 2001, thousands of cattle were slaughtered.[122] Most viral infections of humans and other animals have incubation periods during which the infection causes no signs or symptoms.[13]: 170  Incubation periods for viral diseases range from a few days to weeks, but are known for most infections.[13]: 170–172  Somewhat overlapping, but mainly following the incubation period, there is a period of communicability—a time when an infected individual or animal is contagious and can infect another person or animal.[13]: 170–172  This, too, is known for many viral infections, and knowledge of the length of both periods is important in the control of outbreaks.[13]: 272  When outbreaks cause an unusually high proportion of cases in a population, community, or region, they are called epidemics. If outbreaks spread worldwide, they are called pandemics.[13]: 891 

Epidemics and pandemics

[edit]
An electron micrograph of the virus that caused Spanish influenza
Transmission electron microscope image of a recreated 1918 influenza virus

A pandemic is a worldwide epidemic. The 1918 flu pandemic, which lasted until 1919, was a category 5 influenza pandemic caused by an unusually severe and deadly influenza A virus. The victims were often healthy young adults, in contrast to most influenza outbreaks, which predominantly affect juvenile, elderly, or otherwise-weakened patients.[26]: 409–415  Older estimates say it killed 40–50 million people,[123] while more recent research suggests that it may have killed as many as 100 million people, or 5% of the world's population in 1918.[124]

Although viral pandemics are rare events, HIV—which evolved from viruses found in monkeys and chimpanzees—has been pandemic since at least the 1980s.[125] During the 20th century there were four pandemics caused by influenza virus and those that occurred in 1918, 1957 and 1968 were severe.[126] Most researchers believe that HIV originated in sub-Saharan Africa during the 20th century;[127] it is now a pandemic, with an estimated 37.9 million people now living with the disease worldwide.[128] There were about 770,000 deaths from AIDS in 2018.[129] The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) estimate that AIDS has killed more than 25 million people since it was first recognised on 5 June 1981, making it one of the most destructive epidemics in recorded history.[130] In 2007 there were 2.7 million new HIV infections and 2 million HIV-related deaths.[131]

Ebola (top) and Marburg viruses (bottom)

Several highly lethal viral pathogens are members of the Filoviridae. Filoviruses are filament-like viruses that cause viral hemorrhagic fever, and include ebolaviruses and marburgviruses. Marburg virus, first discovered in 1967, attracted widespread press attention in April 2005 for an outbreak in Angola.[132] Ebola virus disease has also caused intermittent outbreaks with high mortality rates since 1976 when it was first identified. The worst and most recent one is the 2013–2016 West Africa epidemic.[133]

Except for smallpox, most pandemics are caused by newly evolved viruses. These "emergent" viruses are usually mutants of less harmful viruses that have circulated previously either in humans or other animals.[134]

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) are caused by new types of coronaviruses. Other coronaviruses are known to cause mild infections in humans,[135] so the virulence and rapid spread of SARS infections—that by July 2003 had caused around 8,000 cases and 800 deaths—was unexpected and most countries were not prepared.[136]

A related coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), thought to have originated in bats, emerged in Wuhan, China in November 2019 and spread rapidly around the world. Infections with the virus caused the COVID-19 pandemic that started in 2020.[94][137][138] Unprecedented restrictions in peacetime were placed on international travel,[139] and curfews were imposed in several major cities worldwide in response to the pandemic.[140]

Cancer

[edit]

Viruses are an established cause of cancer in humans and other species. Viral cancers occur only in a minority of infected persons (or animals). Cancer viruses come from a range of virus families, including both RNA and DNA viruses, and so there is no single type of "oncovirus" (an obsolete term originally used for acutely transforming retroviruses). The development of cancer is determined by a variety of factors such as host immunity[141] and mutations in the host.[142] Viruses accepted to cause human cancers include some genotypes of human papillomavirus, hepatitis B virus, hepatitis C virus, Epstein–Barr virus, Kaposi's sarcoma-associated herpesvirus and human T-lymphotropic virus. The most recently discovered human cancer virus is a polyomavirus (Merkel cell polyomavirus) that causes most cases of a rare form of skin cancer called Merkel cell carcinoma.[143] Hepatitis viruses can develop into a chronic viral infection that leads to liver cancer.[144][145] Infection by human T-lymphotropic virus can lead to tropical spastic paraparesis and adult T-cell leukaemia.[146] Human papillomaviruses are an established cause of cancers of cervix, skin, anus, and penis.[147] Within the Herpesviridae, Kaposi's sarcoma-associated herpesvirus causes Kaposi's sarcoma and body-cavity lymphoma, and Epstein–Barr virus causes Burkitt's lymphoma, Hodgkin's lymphoma, B lymphoproliferative disorder, and nasopharyngeal carcinoma.[148] Merkel cell polyomavirus closely related to SV40 and mouse polyomaviruses that have been used as animal models for cancer viruses for over 50 years.[149]

Host defence mechanisms

[edit]

The body's first line of defence against viruses is the innate immune system. This comprises cells and other mechanisms that defend the host from infection in a non-specific manner. This means that the cells of the innate system recognise, and respond to, pathogens in a generic way, but, unlike the adaptive immune system, it does not confer long-lasting or protective immunity to the host.[150]

RNA interference is an important innate defence against viruses.[151] Many viruses have a replication strategy that involves double-stranded RNA (dsRNA). When such a virus infects a cell, it releases its RNA molecule or molecules, which immediately bind to a protein complex called a dicer that cuts the RNA into smaller pieces. A biochemical pathway—the RISC complex—is activated, which ensures cell survival by degrading the viral mRNA. Rotaviruses have evolved to avoid this defence mechanism by not uncoating fully inside the cell, and releasing newly produced mRNA through pores in the particle's inner capsid. Their genomic dsRNA remains protected inside the core of the virion.[152][153]

When the adaptive immune system of a vertebrate encounters a virus, it produces specific antibodies that bind to the virus and often render it non-infectious. This is called humoral immunity. Two types of antibodies are important. The first, called IgM, is highly effective at neutralising viruses but is produced by the cells of the immune system only for a few weeks. The second, called IgG, is produced indefinitely. The presence of IgM in the blood of the host is used to test for acute infection, whereas IgG indicates an infection sometime in the past.[154] IgG antibody is measured when tests for immunity are carried out.[155]

Antibodies can continue to be an effective defence mechanism even after viruses have managed to gain entry to the host cell. A protein that is in cells, called TRIM21, can attach to the antibodies on the surface of the virus particle. This primes the subsequent destruction of the virus by the enzymes of the cell's proteosome system.[156]

Two spherical rotavirus particles, one is coated with antibody which looks like many small birds, regularly spaced on the surface of the virus
Two rotaviruses: the one on the right is coated with antibodies that prevent its attachment to cells and infecting them.

A second defence of vertebrates against viruses is called cell-mediated immunity and involves immune cells known as T cells. The body's cells constantly display short fragments of their proteins on the cell's surface, and, if a T cell recognises a suspicious viral fragment there, the host cell is destroyed by 'killer T' cells and the virus-specific T-cells proliferate. Cells such as the macrophage are specialists at this antigen presentation.[157] The production of interferon is an important host defence mechanism. This is a hormone produced by the body when viruses are present. Its role in immunity is complex; it eventually stops the viruses from reproducing by killing the infected cell and its close neighbours.[158]

Not all virus infections produce a protective immune response in this way. HIV evades the immune system by constantly changing the amino acid sequence of the proteins on the surface of the virion. This is known as "escape mutation" as the viral epitopes escape recognition by the host immune response. These persistent viruses evade immune control by sequestration, blockade of antigen presentation, cytokine resistance, evasion of natural killer cell activities, escape from apoptosis, and antigenic shift.[159] Other viruses, called 'neurotropic viruses', are disseminated by neural spread where the immune system may be unable to reach them due to immune privilege.[160]

Prevention and treatment

[edit]

Because viruses use vital metabolic pathways within host cells to replicate, they are difficult to eliminate without using drugs that cause toxic effects to host cells in general. The most effective medical approaches to viral diseases are vaccinations to provide immunity to infection, and antiviral drugs that selectively interfere with viral replication.

Vaccines

[edit]

Vaccination is a cheap and effective way of preventing infections by viruses. Vaccines were used to prevent viral infections long before the discovery of the actual viruses. Their use has resulted in a dramatic decline in morbidity (illness) and mortality (death) associated with viral infections such as polio, measles, mumps and rubella.[161] Smallpox infections have been eradicated.[162] Vaccines are available to prevent over thirteen viral infections of humans,[163] and more are used to prevent viral infections of animals.[164] Vaccines can consist of live-attenuated or killed viruses, viral proteins (antigens), or RNA.[165][166] Live vaccines contain weakened forms of the virus, which do not cause the disease but, nonetheless, confer immunity. Such viruses are called attenuated. Live vaccines can be dangerous when given to people with a weak immunity (who are described as immunocompromised), because in these people, the weakened virus can cause the original disease.[167] Biotechnology and genetic engineering techniques are used to produce subunit vaccines. These vaccines use only the capsid proteins of the virus. Hepatitis B vaccine is an example of this type of vaccine.[168] Subunit vaccines are safe for immunocompromised patients because they cannot cause the disease.[169] The yellow fever virus vaccine, a live-attenuated strain called 17D, is probably the safest and most effective vaccine ever generated.[170]

Antiviral drugs

[edit]
The structure of the DNA base guanosine and the antiviral drug acyclovir

Antiviral drugs are often nucleoside analogues (fake DNA building-blocks), which viruses mistakenly incorporate into their genomes during replication.[171] The life-cycle of the virus is then halted because the newly synthesised DNA is inactive. This is because these analogues lack the hydroxyl groups, which, along with phosphorus atoms, link together to form the strong "backbone" of the DNA molecule. This is called DNA chain termination.[172] Examples of nucleoside analogues are aciclovir for Herpes simplex virus infections and lamivudine for HIV and hepatitis B virus infections. Aciclovir is one of the oldest and most frequently prescribed antiviral drugs.[173] Other antiviral drugs in use target different stages of the viral life cycle. HIV is dependent on a proteolytic enzyme called the HIV-1 protease for it to become fully infectious. There is a large class of drugs called protease inhibitors that inactivate this enzyme.[174] There are around thirteen classes of antiviral drugs each targeting different viruses or stages of viral replication.[171]

Hepatitis C is caused by an RNA virus. In 80% of people infected, the disease is chronic, and without treatment, they are infected for the remainder of their lives. There are effective treatments that use direct-acting antivirals.[175] The treatment of chronic carriers of the hepatitis B virus has also been developed by using similar strategies that include lamivudine and other anti-viral drugs.[176]

Infection in other species

[edit]

Viruses infect all cellular life and, although viruses occur universally, each cellular species has its own specific range that often infects only that species.[6]: 3  Some viruses, called satellites, can replicate only within cells that have already been infected by another virus.[30]

Animal viruses

[edit]

Viruses are important pathogens of livestock. Diseases such as foot-and-mouth disease and bluetongue are caused by viruses.[177] Companion animals such as cats, dogs, and horses, if not vaccinated, are susceptible to serious viral infections. Canine parvovirus is caused by a small DNA virus and infections are often fatal in pups.[178] Like all invertebrates, the honey bee is susceptible to many viral infections.[179] Most viruses co-exist harmlessly in their host and cause no signs or symptoms of disease.[6]: 4 

Plant viruses

[edit]
Peppers infected by mild mottle virus

There are many types of plant viruses, but often they cause only a loss of yield, and it is not economically viable to try to control them. Plant viruses are often spread from plant to plant by organisms, known as vectors. These are usually insects, but some fungi, nematode worms, single-celled organisms, and parasitic plants are vectors.[180] When control of plant virus infections is considered economical, for perennial fruits, for example, efforts are concentrated on killing the vectors and removing alternate hosts such as weeds.[13]: 802  Plant viruses cannot infect humans and other animals because they can reproduce only in living plant cells.[13]: 799–807 

Originally from Peru, the potato has become a staple crop worldwide.[181] The potato virus Y causes disease in potatoes and related species including tomatoes and peppers. In the 1980s, this virus acquired economical importance when it proved difficult to control in seed potato crops. Transmitted by aphids, this virus can reduce crop yields by up to 80 per cent, causing significant losses to potato yields.[182]

Plants have elaborate and effective defence mechanisms against viruses. One of the most effective is the presence of so-called resistance (R) genes. Each R gene confers resistance to a particular virus by triggering localised areas of cell death around the infected cell, which can often be seen with the unaided eye as large spots. This stops the infection from spreading.[183] RNA interference is also an effective defence in plants.[13]: 809  When they are infected, plants often produce natural disinfectants that kill viruses, such as salicylic acid, nitric oxide, and reactive oxygen molecules.[184]

Plant virus particles or virus-like particles (VLPs) have applications in both biotechnology and nanotechnology. The capsids of most plant viruses are simple and robust structures and can be produced in large quantities either by the infection of plants or by expression in a variety of heterologous systems. Plant virus particles can be modified genetically and chemically to encapsulate foreign material and can be incorporated into supramolecular structures for use in biotechnology.[185]

Bacterial viruses

[edit]
An electron micrograph showing a portion of a bacterium covered with viruses
Transmission electron micrograph of multiple bacteriophages attached to a bacterial cell wall

Bacteriophages are a common and diverse group of viruses and are the most abundant biological entity in aquatic environments—there are up to ten times more of these viruses in the oceans than there are bacteria,[186] reaching levels of 250,000,000 bacteriophages per millilitre of seawater.[187] These viruses infect specific bacteria by binding to surface receptor molecules and then entering the cell. Within a short amount of time, in some cases, just minutes, bacterial polymerase starts translating viral mRNA into protein. These proteins go on to become either new virions within the cell, helper proteins, which help assembly of new virions, or proteins involved in cell lysis. Viral enzymes aid in the breakdown of the cell membrane, and, in the case of the T4 phage, in just over twenty minutes after injection over three hundred phages could be released.[13]: 834–835 

The major way bacteria defend themselves from bacteriophages is by producing enzymes that destroy foreign DNA. These enzymes, called restriction endonucleases, cut up the viral DNA that bacteriophages inject into bacterial cells.[188] Bacteria also contain a system that uses CRISPR sequences to retain fragments of the genomes of viruses that the bacteria have come into contact with previously, which allows them to block the virus's replication through a form of RNA interference.[189][190] This genetic system provides bacteria with acquired immunity to infection.[191]

Some bacteriophages are called "temperate" because they cause latent infections and do not immediately destroy their host cells. Instead, their DNA is incorporated with the host cell's as a prophage. These latent infections become productive when the prophage DNA is activated by stimuli such as changes in the environment.[192] The intestines of animals, including humans, contain temperate bacteriophages, which are activated by various stimuli including changes in diet and antibiotics.[193] Although first observed in bacteriophages, many other viruses are known to form proviruses including HIV.[192][194]

Archaeal viruses

[edit]

Some viruses replicate within archaea: these are DNA viruses with unusual and sometimes unique shapes.[4][55] These viruses have been studied in most detail in the thermophilic archaea, particularly the orders Sulfolobales and Thermoproteales.[195] Defences against these viruses involve RNA interference from repetitive DNA sequences within archaean genomes that are related to the genes of the viruses.[196][197] Most archaea have CRISPR–Cas systems as an adaptive defence against viruses. These enable archaea to retain sections of viral DNA, which are then used to target and eliminate subsequent infections by the virus using a process similar to RNA interference.[198]

Role in aquatic ecosystems

[edit]

Viruses are the most abundant biological entity in aquatic environments.[2] There are about ten million of them in a teaspoon of seawater.[199] Most of these viruses are bacteriophages infecting heterotrophic bacteria and cyanophages infecting cyanobacteria and they are essential to the regulation of saltwater and freshwater ecosystems.[200] Bacteriophages are harmless to plants and animals, and are essential to the regulation of marine and freshwater ecosystems[201] are important mortality agents of phytoplankton, the base of the foodchain in aquatic environments.[202] They infect and destroy bacteria in aquatic microbial communities, and are one of the most important mechanisms of recycling carbon and nutrient cycling in marine environments. The organic molecules released from the dead bacterial cells stimulate fresh bacterial and algal growth, in a process known as the viral shunt.[203] In particular, lysis of bacteria by viruses has been shown to enhance nitrogen cycling and stimulate phytoplankton growth.[204] Viral activity may also affect the biological pump, the process whereby carbon is sequestered in the deep ocean.[205]

Microorganisms constitute more than 90% of the biomass in the sea. It is estimated that viruses kill approximately 20% of this biomass each day and that there are 10 to 15 times as many viruses in the oceans as there are bacteria and archaea.[206] Viruses are also major agents responsible for the destruction of phytoplankton including harmful algal blooms,[207] The number of viruses in the oceans decreases further offshore and deeper into the water, where there are fewer host organisms.[205]

In January 2018, scientists reported that 800 million viruses, mainly of marine origin, are deposited daily from the Earth's atmosphere onto every square meter of the planet's surface, as the result of a global atmospheric stream of viruses, circulating above the weather system but below the altitude of usual airline travel, distributing viruses around the planet.[208][209]

Like any organism, marine mammals are susceptible to viral infections. In 1988 and 2002, thousands of harbour seals were killed in Europe by phocine distemper virus.[210] Many other viruses, including caliciviruses, herpesviruses, adenoviruses and parvoviruses, circulate in marine mammal populations.[205]

In December 2022, scientists reported the first observation of virovory via an experiment on pond water containing chlorovirus, which commonly infects green algae in freshwater environments. When all other microbial food sources were removed from the water, the ciliate Halteria was observed to have increased in number due to the active consumption of chlorovirus as a food source instead of its typical bacterivore diet.[211][212]

Role in evolution

[edit]

Viruses are an important natural means of transferring genes between different species, which increases genetic diversity and drives evolution.[9][213][214] It is thought that viruses played a central role in early evolution, before the diversification of the last universal common ancestor into bacteria, archaea and eukaryotes.[215] Viruses are still one of the largest reservoirs of unexplored genetic diversity on Earth.[205]

Applications

[edit]

Life sciences and medicine

[edit]
Scientist studying the H5N1 influenza virus

Viruses are important to the study of molecular and cell biology as they provide simple systems that can be used to manipulate and investigate the functions of cells.[26]: 8  The study and use of viruses have provided valuable information about aspects of cell biology.[216] For example, viruses have been useful in the study of genetics and helped our understanding of the basic mechanisms of molecular genetics, such as DNA replication, transcription, RNA processing, translation, protein transport, and immunology.

Geneticists often use viruses as vectors to introduce genes into cells that they are studying. This is useful for making the cell produce a foreign substance, or to study the effect of introducing a new gene into the genome. Similarly, virotherapy uses viruses as vectors to treat various diseases, as they can specifically target cells and DNA. It shows promising use in the treatment of cancer and in gene therapy. Eastern European scientists have used phage therapy as an alternative to antibiotics for some time, and interest in this approach is increasing, because of the high level of antibiotic resistance now found in some pathogenic bacteria.[217] The expression of heterologous proteins by viruses is the basis of several manufacturing processes that are currently being used for the production of various proteins such as vaccine antigens and antibodies. Industrial processes have been recently developed using viral vectors and several pharmaceutical proteins are currently in pre-clinical and clinical trials.[218]

Virotherapy

[edit]

Virotherapy involves the use of genetically modified viruses to treat diseases.[219] Viruses have been modified by scientists to reproduce in cancer cells and destroy them but not infect healthy cells. Talimogene laherparepvec (T-VEC), for example, is a modified herpes simplex virus that has had a gene, which is required for viruses to replicate in healthy cells, deleted and replaced with a human gene (GM-CSF) that stimulates immunity. When this virus infects cancer cells, it destroys them and in doing so the presence the GM-CSF gene attracts dendritic cells from the surrounding tissues of the body. The dendritic cells process the dead cancer cells and present components of them to other cells of the immune system.[220] Having completed successful clinical trials, the virus gained approval for the treatment of melanoma in late 2015.[221] Viruses that have been reprogrammed to kill cancer cells are called oncolytic viruses.[222]

Materials science and nanotechnology

[edit]

From the viewpoint of a materials scientist, viruses can be regarded as organic nanoparticles.[223] Their surface carries specific tools that enable them to cross the barriers of their host cells. The size and shape of viruses and the number and nature of the functional groups on their surface are precisely defined. As such, viruses are commonly used in materials science as scaffolds for covalently linked surface modifications. A particular quality of viruses is that they can be tailored by directed evolution. The powerful techniques developed by life sciences are becoming the basis of engineering approaches towards nanomaterials, opening a wide range of applications far beyond biology and medicine.[224] Because of their size, shape, and well-defined chemical structures, viruses have been used as templates for organising materials on the nanoscale. Examples include the work at the Naval Research Laboratory in Washington, D.C., using Cowpea mosaic virus (CPMV) particles to amplify signals in DNA microarray based sensors. In this application, the virus particles separate the fluorescent dyes used for signalling to prevent the formation of non-fluorescent dimers that act as quenchers.[225] Another example is the use of CPMV as a nanoscale breadboard for molecular electronics.[226]

Synthetic viruses

[edit]

Many viruses can be synthesised de novo ("from scratch"). The first synthetic virus was created in 2002.[227] Although somewhat of a misconception, it is not the actual virus that is synthesised, but rather its DNA genome (in case of a DNA virus), or a cDNA copy of its genome (in case of RNA viruses). For many virus families the naked synthetic DNA or RNA (once enzymatically converted back from the synthetic cDNA) is infectious when introduced into a cell. That is, they contain all the necessary information to produce new viruses. This technology is now being used to investigate novel vaccine strategies.[228] The ability to synthesise viruses has far-reaching consequences, since viruses can no longer be regarded as extinct, as long as the information of their genome sequence is known and permissive cells are available. As of June 2021, the full-length genome sequences of 11,464 different viruses, including smallpox, are publicly available in an online database maintained by the National Institutes of Health.[229]

Weapons

[edit]

The ability of viruses to cause devastating epidemics in human societies has led to the concern that viruses could be weaponised for biological warfare. Further concern was raised by the successful recreation of the infamous 1918 influenza virus in a laboratory.[230] The smallpox virus devastated numerous societies throughout history before its eradication. There are only two centres in the world authorised by the WHO to keep stocks of smallpox virus: the State Research Center of Virology and Biotechnology VECTOR in Russia and the Centers for Disease Control and Prevention in the United States.[231] It may be used as a weapon,[231] as the vaccine for smallpox sometimes had severe side-effects, it is no longer used routinely in any country. Thus, much of the modern human population has almost no established resistance to smallpox and would be vulnerable to the virus.[231]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
A virus is an acellular infectious agent composed of a nucleic acid genome—either DNA or RNA—enclosed in a protective protein capsid, with some possessing an additional lipid envelope derived from the host cell membrane.[1] Ultramicroscopic in size (typically 20–400 nm), viruses lack cellular structures such as ribosomes, cytoplasm, and independent metabolic machinery, rendering them obligate intracellular parasites that depend entirely on host cells for replication across all domains of life, including bacteria, archaea, plants, and animals.[2][3] Viruses replicate through attachment to host receptors, genome injection or endocytosis, hijacking of host transcription and translation, virion assembly, and release via lysis or budding, enabling rapid evolution via high mutation rates.[4] Classified by systems like Baltimore's, which groups them by genome type and mRNA synthesis, viruses exert ecological influence through gene transfer and biodiversity shaping, cause diseases ranging from acute infections to chronic conditions and oncogenesis, and find applications in gene therapy, vaccines, and phage therapy against antibiotic-resistant bacteria.[3] Although failing standard life criteria due to inability to self-replicate or metabolize independently, their genetic complexity and adaptability sustain debates on their "living" status.[5]

History

Etymology

The word virus derives from Latin vīrus, meaning "poison," "plant sap," or "slimy liquid."[6] It traces to Proto-Italic *weis-o-(s-), denoting poison, with possible cognates like Old Church Slavonic višnja ("cherry"), suggesting links to toxic fruits.[6] In English, virus first appeared in the late 14th century, borrowed from Latin for a poisonous substance, as in John Trevisa's translation of Bartholomaeus Anglicus (c. 1398). By the 1590s, it referred to "venomous exudation from a living body," and by 1798, to agents causing infectious disease.[6] The modern scientific sense—for submicroscopic infectious agents—emerged in 1883, amid discoveries of filterable agents smaller than bacteria.[6][7] This usage preserved the idea of an invisible, noxious toxin, matching observations of contagion without visible microbes.[8]

Early Observations

In 1892, Russian microbiologist Dmitri Ivanovsky filtered sap from tobacco plants with mosaic disease—first described by Adolf Mayer in 1879—through Chamberland porcelain filters that retained bacteria. The filtrate remained infectious on healthy plants, suggesting an ultrafilterable agent smaller than known pathogenic bacteria. Ivanovsky initially viewed this as a bacterial toxin or dissolved enzyme, as it did not form colonies in culture.[9] [10][11] These results challenged the germ theory, which linked diseases mainly to cultivable bacteria per Robert Koch's postulates from the 1880s. In 1898, Dutch microbiologist Martinus Beijerinck replicated Ivanovsky's experiments, using serial dilutions to show infectivity diluted predictably, ruling out persistent toxins. Beijerinck coined contagium vivum fluidum ("contagious living fluid") for this self-replicating, non-cellular entity that multiplied only in host cells, distinguishing it from bacteria and founding virology.[12][12] [13] That same year, German scientists Friedrich Loeffler and Paul Frosch observed similar filtration for foot-and-mouth disease in cattle, the first in animals. The agent passed bacteria-retaining filters and required living host tissue, broadening the paradigm to animal diseases. These findings established submicroscopic, filter-passing pathogens—later called viruses—as causes of certain diseases, unable to metabolize or grow independently, thus reevaluating infectious causation.[14] [13][12]

Scientific Discovery

In 1892, Russian biologist Dmitri Ivanovsky filtered sap from tobacco plants with mosaic disease through porcelain Chamberland filters that retained bacteria. The filtrate infected healthy plants upon inoculation, indicating a causal agent smaller than bacteria or possibly a toxin. Ivanovsky initially favored a toxin but noted the agent's persistence and infectivity, providing the first evidence of a filterable pathogen.[9][15] In 1898, Dutch microbiologist Martinus Beijerinck replicated the filtration experiments and showed the agent multiplied in host tissues, inconsistent with a static toxin. He termed it contagium vivum fluidum, a self-replicating fluid requiring living cells and distinguishing it from bacteria.[16] That year, German scientists Friedrich Loeffler and Paul Frosch filtered lymph from cattle with foot-and-mouth disease, identifying the first animal virus transmissible via filtrate and extending the concept beyond plants.[17] In the 1930s, viruses transitioned from abstract entities to tangible macromolecules. In 1935, American biochemist Wendell Stanley crystallized tobacco mosaic virus (TMV) as a nucleoprotein; redissolved crystals retained infectivity, challenging fluid-only views and highlighting viruses' molecular nature and self-assembly.[18][15] Electron microscopy in the late 1930s enabled direct visualization. In 1939, Helmut Ruska and colleagues imaged TMV as rod-shaped particles about 300 nm long, confirming their submicroscopic particulate form. 1940 micrographs revealed bacteriophages' tadpole-like structures attached to bacteria.[19] These findings established viruses as discrete obligate intracellular parasites, founding virology as a field.[20]

Hypotheses on Viral Origins

Virus origins remain unresolved, with three main hypotheses—progressive (escape), regressive (reduction), and virus-first (co-evolution)—drawn from comparative genomics, evolutionary modeling, and replication strategies. Evidence is indirect, mainly from genome sequences blending cellular-like and unique genes, with no viral fossils before cellular life around 3.5–4 billion years ago. No hypothesis explains all viral diversity, from high-mutation RNA viruses to large DNA viruses encoding hundreds of proteins.[21][22] The progressive hypothesis suggests viruses arose from intragenomic elements like plasmids or transposons that gained capsid proteins and egress mechanisms for cell-to-cell transmission. Support comes from viral genes resembling host mobile elements and their integration into eukaryotic genomes, as seen in retroviruses like HIV from endogenous elements comprising up to 8% of the human genome. However, it fails to account for viruses with unique polymerases lacking cellular homologs.[21][23][24] In contrast, the regressive hypothesis proposes viruses descended from free-living or parasitic cells, such as ancient bacteria or symbionts, that lost metabolic genes via reductive evolution while retaining host-dependent replication. Giant viruses like Mimivirus, with over 900 genes including translation components—more than some unicellular parasites—and amoeba hosts, bolster this view, mirroring obligate intracellular bacteria's genome shrinkage. Yet it conflicts with viral diversification postdating major cellular domains.[21][22][24] The virus-first hypothesis posits viruses or replicators predated or co-evolved with cells, emerging from pre-cellular RNA-protein complexes that transferred genes to cellular genomes. It draws on the RNA world's self-replicating ribozymes, akin to simple RNA viruses under 10 kb, and viral genes comprising 10–20% of some cellular proteomes via horizontal transfer. Félix d'Herelle suggested an early form in the 1920s. Drawbacks include DNA viruses' complexity and the dependence of all known viruses on cells.[21][25][24] Phylogenetic analyses suggest polyphyletic origins: RNA viruses from early RNA-world escapes, DNA viruses from cellular reductions. Metagenomic surveys of ocean viruses reveal novel lineages, highlighting the hypotheses' provisional status amid an estimated global virosphere of 10^31 particles.[26][22]

Biological Characteristics

Debate on Viral Life Status

The classification of viruses as living or non-living remains unresolved, due to ambiguities in defining life. Viruses fail traditional criteria such as cellular organization, independent metabolism, homeostasis, growth, and autonomous reproduction, as their acellular virions lack ribosomes, enzymes for energy production, or self-maintenance outside a host. Extracellular virions show no metabolic activity and cannot replicate without host machinery, acting as inert genetic packages.[27] [28] [29] [30] Opponents of viral life status stress obligate parasitism: viruses rely on host cells for protein synthesis, energy, and replication, limiting independent Darwinian evolution per definitions like NASA's self-sustaining chemical system capable of evolution. The International Committee on Taxonomy of Viruses (ICTV) views them as distinct from cellular life, without vitality. Critics argue that replication metaphors overlook host dependency, where viruses direct but do not originate processes.[5] [31] [32] In contrast, proponents cite viruses' genetic complexity, mutation capacity, natural selection, and shared molecular components (DNA or RNA in protein coats) with cells, viewing them as primitive or derived life forms. The "virocell" concept posits infected cells as viral factories with emergent replication and evolvability beyond inert virions. Viruses co-evolved with hosts, sharing genes and driving biodiversity, blurring life boundaries. Yet these views are challenged for conflating host-virus interactions with intrinsic vitality, absent without cellular support.[33] [34] [29] [35] [36] No scientific consensus exists; most biologists classify viruses as non-living for failing core criteria, though debate continues amid definitional fluidity and evolutionary roles. Virologists like Eugene Koonin deem the question peripheral, as viruses replicate effectively regardless of labels, favoring operational biology over taxonomy. This reflects causal realism in virology: viruses profoundly impact living systems via genetic hijacking, despite lacking independent agency in extracellular form.[37] [38] [39] [40]

Structural Components

Viruses consist of a nucleic acid genome enclosed in a protein capsid, forming the nucleocapsid of the virion.[1] The capsid protects the genome from damage, enables host cell attachment, and aids entry.[41] Non-enveloped viruses expose the capsid outermost, whereas enveloped viruses surround the nucleocapsid with a lipid bilayer membrane.[1] Capsids assemble from repeating capsomeres, each made of one or more protomer protein subunits.[1] They display three main symmetries: helical, as in tobacco mosaic virus where proteins coil around the genome; icosahedral, forming a near-20-sided polyhedron in adenoviruses for efficient enclosure with minimal protein; and complex, with added features like tails, base plates, and fibers in T4 bacteriophages for host recognition.[1] These symmetries shape virion form; icosahedral capsids use T-numbers (e.g., T=1 simplest, up to T=25 or more) to determine subunit arrangement and stability.[1] Enveloped viruses obtain their lipid envelope from host membranes during budding, embedding glycoproteins as spikes for receptor binding and membrane fusion.[1] A matrix protein layer beneath may stabilize the envelope and connect it to the nucleocapsid, as with influenza's M1 protein in assembly.[41] Some virions contain internal enzymes like polymerases in the capsid for prompt replication, though not all do.[1] Sizes range from 20 nm in small RNA viruses like picornaviruses to over 300 nm in complex poxviruses.[37]

Genetic Material and Genome Features

Viruses possess genetic material of either DNA or RNA, serving as the blueprint for replication and protein synthesis. This nucleic acid may be single-stranded (ss) or double-stranded (ds), linear or circular, and occasionally segmented. Such diversity enables adaptation to host replication machinery and evasion of defenses, unlike the universal dsDNA of cellular organisms.[42][43] Viral genome sizes range from under 3 kilobases (kb) in small ssDNA viruses like geminiviruses (~2,580 nucleotides) to over 2 megabases (Mb) in giant dsDNA viruses such as pandoraviruses (~2.5 Mb, encoding nearly 2,500 proteins). Typical non-giant genomes span 7–20 kb, including parvoviruses with 4–6 kb ss linear DNA and mimiviruses with 1.2 Mb dsDNA. This variation aligns with capsid size and gene count, from few genes in minimal viruses to hundreds in larger ones—still fewer than the smallest cellular genomes.[44][45][1][46][47] Viral genomes exhibit extreme compactness, with high gene density and frequent overlapping genes encoding multiple proteins via different reading frames. RNA viruses produce polyproteins cleaved post-translationally, while both DNA and RNA genomes generally lack introns and extensive non-coding regions. Mutation rates surpass those of cellular life, especially in RNA viruses (~10^{-4} substitutions per nucleotide per cycle) due to error-prone polymerases, driving rapid evolution; DNA viruses mutate more slowly by borrowing host proofreading enzymes. These features allow viruses to exploit host resources with minimal self-sufficiency.[48][49][50][47]

Host Dependency and Range

Viruses are obligate intracellular parasites lacking ribosomes, metabolic enzymes, and energy production, requiring host cellular machinery for genome duplication, protein synthesis, and virion assembly.[21] This confines propagation to viable host cells, where viruses direct ribosomes to translate viral messenger RNA and commandeer nucleotide pools and polymerases for nucleic acid replication.[51] Outside hosts, they persist as inert particles resistant to environmental stresses but unable to propagate without cellular invasion.[52] Host range spans susceptible species, cell types, or strains, mainly determined by receptor-binding specificity of viral surface proteins to host receptors.[53] Intracellular barriers, such as uncoating efficiency, use of host replication factors, and evasion of antiviral defenses like interferon responses or restriction factors, further limit range.[54] In influenza A viruses, host specificity stems from hemagglutinin adaptations to sialic acid linkages—α-2,6 in humans versus α-2,3 in birds—allowing occasional avian strains to adapt for mammalian transmission.[55] Viruses exhibit host ranges from narrow to broad, affecting transmission and zoonotic potential. Narrow examples include infectious hematopoietic necrosis virus (IHNV), limited to salmonid fish due to strict receptor and replication compatibilities.[56] Broadly, cucumber mosaic virus infects over 1,200 plant species across families, reflecting receptor promiscuity and adaptability.[57] SARS-CoV-2 shows intermediate range, infecting primates, felines, mustelids, and suids via angiotensin-converting enzyme 2 (ACE2) variations, but inefficiently in rodents without adaptation.[58] Bacteriophages usually target specific strains within bacterial genera, though host selection can produce variants lysing multiple strains.[59] Host range expansions arise from mutations in attachment proteins or recombination with co-infecting viruses, as in influenza pandemics from avian reservoirs adapting to humans.[55] These shifts link ecological interfaces, like wildlife-livestock contacts, to emergence risks, with surveillance showing most human viruses originate in animals.[56] Within hosts, tissue tropism provides further specificity; for instance, poliovirus targets neuronal cells via receptor distribution, heightening pathogenicity despite broader in vitro susceptibility.[60]

Replication and Dynamics

Infection Mechanisms

Viruses attach to specific host cell surface receptors via viral surface proteins, such as glycoproteins on enveloped viruses or capsid proteins on non-enveloped ones, which interact with host proteins, carbohydrates, or lipids.[61] This binding determines host range and tropism by limiting infection to cells expressing compatible receptors; for example, HIV targets CD4 on T cells, while influenza A virus binds sialic acid residues.[62] Attachment typically triggers conformational changes in viral proteins, preparing for entry, often with co-receptors for added specificity. Entry pathways vary by viral structure and host. Enveloped viruses may fuse directly at the plasma membrane, where fusion proteins like influenza hemagglutinin rearrange to merge the viral envelope with the host lipid bilayer, releasing the capsid into the cytoplasm, or enter via endocytosis, with endosomal low pH activating fusion as in HIV and Ebola.[63][64] Non-enveloped viruses rely on endocytosis—through clathrin pits, caveolae, or macropinocytosis—followed by endosomal escape via capsid disassembly, pore formation, or membrane penetration, as in adenoviruses using protein VI for lysis.[65] Bacteriophages infecting bacteria often inject nucleic acid directly through the cell wall and membrane using tail fibers and a syringe-like structure, bypassing endocytosis, as in T4 phage breaching peptidoglycan.[66] These processes exploit host machinery while evading defenses like phagocytosis, with efficiency depending on receptor density and viral titer. Mismatches in receptors or host restrictions drive viral specificity and guide antiviral strategies.[67][68]

Replication Cycle

Viruses lack independent metabolic machinery and replicate only within host cells, hijacking cellular ribosomes, enzymes, and energy for genome duplication and protein synthesis.[4] The typical cycle includes attachment, penetration, uncoating, replication, assembly, maturation, and release, though details vary by viral family.[69][70] Attachment begins as viral capsid or envelope glycoproteins bind specific host cell receptors, determining tropism and host range.[70] Penetration follows via receptor-mediated endocytosis, direct membrane fusion (enveloped viruses), or nucleic acid injection (bacteriophages).[69] Uncoating then dismantles the capsid with host or viral proteases, releasing the genome into the cytoplasm or nucleus.[70] Replication uses host machinery: DNA viruses typically transcribe mRNA and replicate in the nucleus via cellular polymerases, while RNA viruses often function in the cytoplasm—positive-sense RNA serving as mRNA and negative-sense requiring viral RNA-dependent RNA polymerase.[4] Retroviruses like HIV reverse-transcribe RNA to DNA for nuclear integration.[4] Viral proteins, including structural ones, translate on host ribosomes.[70] Assembly packages replicated genomes with proteins into progeny virions, often via spontaneous self-assembly; maturation may involve proteolytic cleavage for infectivity.[4] Release disperses virions: non-enveloped viruses lyse host cells in the lytic cycle, while enveloped ones bud, acquiring lipid envelopes from host membranes without immediate lysis.[70][69] Bacteriophages show lytic cycles ending in host lysis or lysogenic cycles integrating phage DNA as prophage into bacterial genomes, replicating passively during cell division until cues induce lysis.[71] Eukaryotic viruses like herpesviruses exhibit analogous latency, persisting as genomes to evade immunity without active production.[4]

Genetic Variation and Evolution

Viruses show high genetic variation from error-prone replication, allowing rapid evolution against host immunity and antivirals. RNA viruses mutate at 10^{-6} to 10^{-4} substitutions per nucleotide per cycle—far exceeding DNA viruses' 10^{-8} to 10^{-6} rates—due to lacking proofreading in RNA-dependent RNA polymerases.[72][73] DNA viruses often use host proofreading enzymes for greater fidelity.[74] Short generation times and large populations amplify this diversity per infection.[75] Viruses also diversify via recombination, swapping segments between co-infecting strains, and reassortment in segmented genomes. Recombination involves template switching or nucleic acid breakage and rejoining, common in RNA viruses like coronaviruses and retroviruses.[76][77] Reassortment, seen in influenza, mixes entire gene segments from co-infecting parents, aiding host jumps or immunity evasion.[78] These mechanisms boost variation, with natural selection favoring adaptive variants amid genetic drift and transmission bottlenecks.[79] The quasispecies model views viral populations as mutant swarms, not uniform clones, when mutations surpass the error threshold. Intra-host diversity supports adaptation, as defective genomes may complement fitter ones, though selection eliminates harmful variants. RNA viruses like poliovirus maintain these swarms for resilience.[80][81][82] Evolutionary rates differ widely—spanning six orders of magnitude—driven by genome structure, replication speed, and selection, beyond just mutation rates.[79] HIV-1 evolves at ~10^{-3} substitutions per site per year via reverse transcriptase errors and recombination, fostering immune escape and drug resistance.[83] Influenza A experiences antigenic drift from mutations in hemagglutinin and neuraminidase, requiring yearly vaccine updates, while reassortment sparked pandemics like 1957 (H2N2) and 1968 (H3N2).[84] SARS-CoV-2 mutates slower at ~10^{-3} per site per year, but variants like Omicron (B.1.1.529, November 2021) arose via recombination and selection for transmissibility and evasion.[85][86] Host factors and transmission limit this adaptive potential.[87]

Persistent and Latent Infections

Persistent infections occur when a virus maintains long-term presence in the host without clearance, often through low-level continuous or intermittent replication that avoids rapid cell destruction or immune elimination.[88] Unlike acute infections, they extend beyond the initial symptomatic phase via mechanisms like antigenic variation, downregulated viral gene expression, or genome integration, evading adaptive immunity while remaining infectious in reservoirs such as lymphocytes or epithelial cells.[88] Host factors, including immune suppression or genetic predispositions, facilitate persistence by impairing clearance of infected cells.[89] Latent infections, a subset of persistent ones, feature dormant viral genomes in host cells with minimal protein production and no active replication, allowing long-term survival without immediate pathogenesis.[90] Epigenetic silencing of viral promoters—via histone modifications or microRNA interference—represses lytic genes, preserving the genome in episomal or integrated forms, often in non-dividing cells like neurons.[91] Reactivation occurs under stressors such as immunosuppression, hormonal changes, or UV exposure, leading to productive replication and shedding.[92] This enables propagation via asymptomatic carriers, imposing no host fitness cost until reactivation.[93] Persistent infections involve ongoing low-level virion production, sustaining chronic inflammation or immune exhaustion, whereas latency features transcriptional quiescence that promotes immune tolerance without constant antigen exposure.[94] For example, hepatitis B virus (HBV) replicates in hepatocytes via reverse transcription of pregenomic RNA, producing circulating Dane particles and immune complex-mediated liver damage over decades.[88] In contrast, herpes simplex virus type 1 (HSV-1) establishes latency in trigeminal ganglia, where the episomal genome expresses only latency-associated transcripts (LATs), suppressing lytic genes until stress triggers reactivation and recurrent oral lesions in 20-40% of carriers annually.[95] Human immunodeficiency virus (HIV) combines features, with latent reservoirs in resting CD4+ T cells featuring integrated, transcriptionally silent proviral DNA due to chromatin compaction, resisting therapy and enabling rebound.[89] Epstein-Barr virus latency in B lymphocytes, via restricted gene expression, links to oncogenic risks like Burkitt's lymphoma.[95] These infections challenge eradication, as antivirals targeting replication spare dormant genomes, requiring latency-reversing agents to expose reservoirs for clearance.[91] Varicella-zoster virus (VZV), for instance, latently persists in dorsal root ganglia after chickenpox, reactivating as shingles in 30% of those over 80 due to waning cell-mediated immunity.[95] Such strategies highlight viral adaptation to host longevity, favoring transmission over virulence.[89]

Classification

ICTV Taxonomic Framework

The International Committee on Taxonomy of Viruses (ICTV), established in 1971 under the International Union of Microbiological Societies, is the global authority for naming and classifying viruses and virus-like entities.[96] It maintains a universal taxonomy based on shared properties, evolutionary relationships, and genetic characteristics, distinguishing viruses as physical entities from the abstract taxa to which they are assigned.[97] This framework excludes viruses from the three-domain system of cellular life (Bacteria, Archaea, Eukarya). Instead, it uses a dedicated hierarchy starting at the realm rank to capture viral diversity.[98] ICTV taxonomy employs up to 15 hierarchical ranks. Expanded in 2020 from five traditional levels (order, family, subfamily, genus, species), this structure aligns with Linnaean principles and divides the virosphere into discrete groups.[99] Ranks, from most to least inclusive, are: realm, subrealm, kingdom, subkingdom, phylum, subphylum, class, subclass, order, suborder, family, subfamily, genus, subgenus, and species.[98] Decisions draw on virion morphology, genome type and organization, replication strategy, and phylogenetic data, with proposals ratified by ICTV executives and study groups.[96] The August 2025 release (after February 2025 ratifications under Master Species List #40) includes 7 realms, 11 kingdoms, 22 phyla, 4 subphyla, 49 classes, 93 orders, 12 suborders, over 800 families, and thousands of species, spurred by viral metagenomics.[100] Key realms are Adnaviria (linear dsDNA in A-form, infecting archaea and bacteria), Duplodnaviria (dsDNA viruses with diverse hosts, including bacteriophages), Monodnaviria (monopartite ssDNA viruses), Riboviria (RNA viruses with RNA-dependent RNA polymerase), Ribozyviria (ribozyme-based replication in viroids and relatives), Shotokuvirae (segmented RNA viruses), and Varidnaviria (vertically transmitted icosahedral dsDNA viruses).[101][102] Higher ranks group viruses by core replication mechanisms and genome structures; lower ranks refine via host range, protein homology, and sequence divergence.[99] Standardized binomial species names (genus epithet plus descriptor) boost precision and genomic database integration.[103] The framework advances via proposals that emphasize monophyly and diagnostic traits over host specificity, despite ongoing debates on uncultured metagenomic viruses.[104] Resources such as the online taxonomy browser and annual reports offer searchable classifications, supporting adaptation to new data without broad revisions.[100] This evidence-based nomenclature enables stable comparisons in virological research.[105]

Baltimore Classification System

The Baltimore classification, proposed by virologist David Baltimore in 1971, groups viruses into seven classes based on nucleic acid type and mRNA synthesis pathway.[106] This scheme emphasizes the central dogma's flow from genome to mRNA, revealing replication strategies beyond morphology or host range.[107] Originally six classes, it later incorporated a seventh for reverse transcriptase-using partially dsDNA viruses.[106] Group I features dsDNA genomes transcribed to mRNA by host RNA polymerase, mirroring cellular processes; examples include adenoviruses, herpesviruses, and poxviruses.[108] Group II has ssDNA genomes converted to dsDNA intermediates for transcription; parvoviruses represent this.[108] Group III uses dsRNA genomes, with viral RNA-dependent RNA polymerase transcribing mRNA from one strand; reoviruses exemplify it.[108] Group IV contains +ssRNA genomes that act directly as mRNA for translation; picornaviruses and coronaviruses fit here.[109] In contrast, Group V's -ssRNA genomes require viral RNA-dependent RNA polymerase for +mRNA synthesis; examples are rhabdoviruses (e.g., rabies virus) and paramyxoviruses (e.g., measles virus).[108] Group VI retroviruses reverse-transcribe +ssRNA to DNA for host genome integration and mRNA production; HIV is prominent.[109] Group VII viruses replicate partially dsDNA genomes via RNA intermediates and reverse transcriptase, as in hepadnaviruses like hepatitis B virus.[106] The system elucidates gene expression, guiding antivirals like reverse transcriptase inhibitors for Groups VI and VII, and complements ICTV taxonomy via mechanistic focus.[107][110]
GroupGenome TypemRNA Synthesis MechanismExamples
IdsDNADirect transcription by host RNA polymeraseAdenoviruses, herpesviruses, poxviruses[108]
IIssDNAConversion to dsDNA, then transcriptionParvoviruses[108]
IIIdsRNATranscription by viral RdRp from dsRNA templateReoviruses[108]
IV+ssRNAGenome serves as mRNAPicornaviruses, coronaviruses[109]
V-ssRNATranscription by viral RdRp to +mRNARhabdoviruses, paramyxoviruses[108]
VI+ssRNA-RTReverse transcription to DNA, integration, then transcriptionRetroviruses (e.g., HIV)[109]
VIIdsDNA-RTRNA intermediate via reverse transcription for replicationHepadnaviruses (e.g., hepatitis B)[106]
RdRp: RNA-dependent RNA polymerase

Phylogenetic and Functional Classifications

Phylogenetic classification reconstructs viral evolution using molecular sequences from conserved genes, built into trees via maximum likelihood or Bayesian methods on aligned nucleotides or amino acids. These trees identify monophyletic clades for taxonomic ranks like genera and species. RNA viruses rely on the RNA-dependent RNA polymerase (RdRp) gene for its ubiquity and conservation, defining realms in the ICTV system.[111][96] DNA viruses use DNA polymerase or major capsid protein sequences, as in tailed bacteriophages where capsid genes align clustering with host specificity and genome structure.[112] This resolves polyphyly debates in double-stranded DNA viruses by tracing genomic ancestries into the tree of life.[113] The ICTV framework emphasizes phylogenetic monophyly[/page/Monophyly], with 2023 updates mapping ranked pyramids onto trees to handle horizontal gene transfer[/page/Horizontal_gene_transfer]. In silico tools for prokaryotic viruses use genetic distances and branch metrics for systematic ranks, surpassing phenotype-based schemes in resolving diversity.[114][115] Full-genome phylogenies outperform partial genes for pathogens like respiratory syncytial virus[/page/Respiratory_syncytial_virus], setting species[/page/Species] boundaries at under 2% distance. Highly mutable RNA[/page/RNA] viruses require multi-locus analyses to counter recombination artifacts.[116][117] Functional classifications group viruses by traits and mechanisms, beyond phylogeny, to highlight adaptations and host interactions. Lytic viruses destroy hosts upon replication, unlike lysogenic ones that integrate dormant genomes, as in temperate bacteriophages.[1] Envelope presence distinguishes transmission and evasion: enveloped viruses gain host lipids for extracellular stability, non-enveloped use durable capsids for fecal-oral routes.[41] Oncogenic viruses, like some papillomaviruses, disrupt cell cycle[/page/Cell_cycle] controls convergently across lineages under shared pressures, not common descent[/page/Common_descent].[118] These schemes reveal convergent evolution[/page/Convergent_evolution] in efficiency or range, forming ecological guilds, but need genetic backing to avoid oversimplification.[115]

Ecological and Evolutionary Roles

In Ecosystems

Viruses rank among the most abundant biological entities, with ~10^{30} particles estimated in oceans alone. Marine concentrations range from 10^6 to 10^8 per milliliter of seawater, exceeding bacteria by an order of magnitude; soil densities reach 10^8 to 10^9 per gram in organic-rich, moist conditions. This abundance positions viruses as key regulators of microbial dynamics across habitats.[119][120][121] Bacteriophages target prokaryotes for lysis, exerting top-down control that curbs bacterial overgrowth and promotes community diversity. This prevents monopolization by dominant species, as shown in cholera outbreaks where phages reshaped bacterial compositions. Phages also induce phenotypic heterogeneity for resilience via varied infection responses and drive co-evolution through Red Queen dynamics, enhancing genetic diversity.[122][123][124] In aquatic ecosystems, the viral shunt lyses microbes to redirect particulate organic matter into dissolved forms that bacteria remineralize, bypassing higher trophic levels. This recycles up to 30% of primary production into the microbial loop, sustaining nutrient availability and shaping biogeochemical cycles, including carbon sequestration. Viral activity thus influences ocean biological pumps and atmospheric CO_2 levels.[125][126][127] Similarly, in terrestrial ecosystems, soil viruses regulate bacterial nitrogen fixation and decomposition. Phage lysis releases bioavailable nitrogen to boost plant productivity, while transduction disseminates genes for faster microbial adaptation. Across environments, viruses enable gene flow between ecosystems, supporting overall balance and function.[128][129][130]

Influence on Host Evolution

Viruses exert strong selective pressures on hosts through differential mortality and reproduction, favoring variants with resistance or tolerance to infection. This coevolutionary arms race promotes fixation of advantageous mutations, such as those boosting immune responses or modifying viral entry receptors. Empirical evidence from natural and experimental systems shows viral epidemics rapidly alter allele frequencies, often via standing genetic variation rather than novel mutations.[131][132] A key example is the coevolution of myxoma virus (MYXV) and European rabbits (Oryctolagus cuniculus) after its 1950 introduction in Australia for biocontrol. Initially lethal to over 99% of infected rabbits, the virus saw host survival rise to 70-90% within a decade, driven by resistance traits like enhanced innate immunity and reduced viral replication. The virus also attenuated, balancing transmission with lower virulence in field isolates. Independent adaptations in Australian, European, and Chilean populations targeted similar immune genes, such as those in the TLR2 pathway, highlighting predictable selection under viral pressure.[133][132][134] Endogenous retroviruses (ERVs), ancient viral insertions into germline DNA, have shaped mammalian evolution by supplying co-opted genetic elements. ERVs form 8-10% of the human genome and include genes like syncytin-1, from HERV-W envelopes, which enables trophoblast fusion for placental development in eutherians—a feature absent in marsupials. This exaptation supported viviparity's emergence 100-150 million years ago, with syncytin orthologs conserved across species from independent captures. Though most ERVs are epigenetically silenced to avert pathogenesis, their sequences affect gene expression, immunity, and development, illustrating viruses' roles as both parasites and innovators.[135][136][137] In humans, the CCR5-Δ32 deletion, found in ~10% of Europeans (1% homozygous), disrupts the CCR5 coreceptor to block HIV-1 entry by R5-tropic strains, which cause most infections. Originating 700-5,000 years ago with a clinal frequency gradient, it likely spread via selection from epidemics like smallpox or bubonic plague, as CCR5 influences responses to these pathogens. HIV continues selecting for it in high-risk groups, without apparent fitness costs for homozygotes. These cases show viruses driving defensive traits and broader immune evolution.[138][139][140]

Viral Diversity and Discovery

Viruses are Earth's most abundant biological entities, estimated at 10^{31} particles across oceans, soils, and hosts—vastly outnumbering stars in the observable universe.[141][142] This scale reflects their immense diversity in genetics, structure, and host range, spanning infections of bacteria, archaea, eukaryotes, and even other viruses. The International Committee on Taxonomy of Viruses (ICTV) classifies about 14,690 species as of 2023, yet extrapolations estimate 10^7 to 10^9 globally, including over 1 million in mammals alone.[103][143][144] Known viruses thus capture only a fraction of the virosphere, skewed by sampling biases favoring pathogenic or culturable strains. Early discoveries relied on indirect evidence and basic techniques. In 1892, Dmitri Ivanovsky showed tobacco mosaic disease passed through bacteria-retaining filters, suggesting a sub-bacterial agent; Martinus Beijerinck confirmed this in 1898 as a "contagium vivum fluidum."[12] Bacteriophages appeared in 1915 (Frederick Twort) and 1917 (Félix d'Herelle), visualized via plaque assays on bacterial lawns.[12] Electron microscopy from the 1930s revealed morphologies like icosahedral and helical capsids, while 1940s–1950s cell cultures isolated animal viruses such as poliovirus.[145] These methods prioritized lab-propagable viruses, overlooking much environmental and asymptomatic diversity. Modern approaches favor culture-independent techniques, especially viral metagenomics with next-generation sequencing (NGS). These sequence nucleic acids from samples, assembling genomes de novo to reveal novel families like mimiviruses and RNA viromes in uncultured environments.[146][147] Ocean viromes, for example, expose billions of phage types influencing bacterial mortality, while mammalian meta-transcriptomics detects hundreds of thousands of RNA viruses.[148] Bioinformatics filters non-viral sequences, spots viral markers (e.g., capsid genes), and classifies using features like RNA-dependent RNA polymerase, though viable viruses remain hard to distinguish from fragments and assemblies often stay incomplete.[149][150] Discovery accelerates without plateau, driven by sampling underrepresented hosts like invertebrates and protists.[151]

Pathogenicity and Disease

Mechanisms of Disease Causation

Viruses initiate disease by attaching to host cell receptors, which dictate tissue tropism, then entering via endocytosis or fusion, uncoating, and replicating using host machinery.[152] This process disrupts cellular functions, causing direct cytopathic effects (CPE) such as cell lysis from virion accumulation and membrane rupture; apoptosis via viral activation of host caspases; syncytium formation in viruses like measles; or inclusion bodies from aggregated viral components.[152] [153] [154] For example, poliovirus recruits phosphatidylinositol 4-kinase to alter membranes, triggering osmotic lysis in neurons.[154] In cytopathic viruses like influenza A or herpes simplex, CPE destroys respiratory or skin epithelial cells, impairing barriers and sparking inflammation.[155] [156] In contrast, viruses such as hepatitis B (HBV) or HIV show limited direct CPE, with pathology arising mainly from host immunity. Cytotoxic CD8+ T cells lyse infected cells displaying viral antigens on MHC class I, amplifying damage in heavily infected tissues—as in HBV chronic hepatitis, where T-cell infiltration causes hepatocyte necrosis and fibrosis.[155] [157] Immune responses exacerbate injury through cytokine overproduction (e.g., interferon-gamma, tumor necrosis factor-alpha), leading to cytokine storms that boost vascular permeability and inflammation beyond viral replication, as in severe influenza or Ebola.[157] [155] Antibody-dependent enhancement worsens infections like dengue via non-neutralizing antibodies aiding viral entry into immune cells. Persistent infections drive chronic damage via sustained replication and immune activation, including autoimmune responses or T-cell exhaustion, as in HIV depleting CD4+ cells.[154] [152] Unlike bacteria, viruses seldom produce exotoxins but can mimic them, such as HIV's Tat protein causing neurotoxicity through excitotoxicity.[156] Viral dissemination via primary viremia reaches target organs hematogenously, while neurotropic spread—like rabies axonal transport—bypasses immunity to invade the central nervous system.[152] Host factors, including age, genetics, and coinfections, influence severity; neonates, for instance, face heightened risk from disseminated herpes simplex due to immature adaptive immunity.[156] In vitro CPE assays align with in vivo pathology, though immune effects often dominate in cleared infections.[153][158]

Human Viral Infections

Viruses cause human infections ranging from self-limiting illnesses like the common cold to chronic and fatal diseases. Respiratory viruses drive most acute cases: influenza virus causes about 1 billion infections yearly worldwide, including 3-5 million severe illnesses and 290,000-650,000 respiratory deaths.[159] Respiratory syncytial virus mainly affects infants and the elderly, causing bronchiolitis and pneumonia with millions of lower respiratory infections annually.[160] Human coronaviruses, including endemic strains and SARS-CoV-2 behind COVID-19, contribute to upper and lower respiratory diseases.[161] Gastrointestinal viruses like noroviruses and rotaviruses trigger acute diarrhea, especially in children; rotavirus once led to severe dehydration, but vaccination has cut hospitalizations by over 85% in affected populations.[162] Hepatic viruses such as hepatitis B virus (HBV) and hepatitis C virus (HCV) cause chronic infections: HBV affects 296 million globally (2019 data), progressing to cirrhosis or liver cancer in 15-25% of untreated carriers; HCV infects about 58 million, often silently until advanced damage.[163][163] Herpesviruses—herpes simplex viruses (HSV-1/2), cytomegalovirus (CMV), and Epstein-Barr virus (EBV)—typically establish lifelong latency post-infection. HSV-1 causes oral lesions in 67% of people under 50 worldwide; HSV-2 genital infections affect 13% aged 15-49.[95] CMV infects over 50% of adults by age 40 in developed countries, usually asymptomatically but severely in immunocompromised hosts.[164] EBV, tied to infectious mononucleosis, infects nearly 95% of adults and links to certain lymphomas.[165] Human immunodeficiency virus (HIV) depletes CD4+ T cells, leading to AIDS without treatment; it has caused 40.4 million deaths since 1983, with 39 million living with it in 2023. Transmission mainly occurs via blood, sex, and perinatal routes.[166][167] Emerging threats include Ebola virus disease, with 25-90% fatality rates (strain-dependent), as in the 2014-2016 West African outbreak killing over 11,000, and Zika virus, linked to fetal microcephaly in the 2015-2016 Americas epidemic.[168] These zoonoses underscore wildlife-human interface risks, requiring ongoing surveillance.[169]

Infections in Non-Human Hosts

Viruses infect prokaryotes such as bacteria and archaea. Bacteriophages, the most abundant biological entities on Earth, number over 10^31 particles globally.[170] They modulate bacterial communities by lysing cells, altering abundance, diversity, physiology, and virulence, which influences nutrient cycling and ecosystem dynamics, including nitrogen transformation in soils.[171][128] In marine and gut microbiomes, phages promote bacterial evolution via horizontal gene transfer and selection, sustaining microbial balance and preventing species dominance.[172] Archaeal viruses feature unique morphologies like bottle-shaped or tailed forms and regulate populations in extreme settings such as deep-sea vents, aiding global biogeochemical cycles.[173][174] In animal hosts, viruses form reservoirs that sustain transmission and pose zoonotic threats. Bats, rodents, and birds host high viral diversity, driven by factors like flight-related immune changes and social behaviors.[175] Bats carry many zoonotic viruses asymptomatically, including coronaviruses like SARS-CoV-2 progenitors, filoviruses such as Ebola, and over 20 families overall.[176][177] Rodents transmit hantaviruses and arenaviruses, causing hemorrhagic fevers, while birds amplify avian influenza (e.g., H5N1), spilling over to poultry and mammals.[178] Domestic livestock serve as intermediate hosts, as in Nipah virus transmission from bats via pigs, highlighting wildlife-livestock interfaces in emergence.[179][180] Plant viruses affect crops and wild species, inflicting billions in annual agricultural losses via yield drops and quality declines.[181] Synergistic infections, such as maize chlorotic mottle virus with potyviruses causing maize lethal necrosis disease, ravaged East Africa yields from around 2011.[182] Tobacco mosaic virus and tobamoviruses persist in soil and on surfaces, spreading mechanically or by insects to solanaceous crops.[183] Aphid-vectored Luteoviridae manipulate insect behavior for better transmission.[184] In non-crop settings, these viruses alter weed dynamics and infect ornamentals, though RNA silencing curbs spread in resistant hosts.[185] Viruses infect fungi (mycoviruses) and protists, albeit less studied. Mycoviruses often remain latent, reducing host virulence; double-stranded RNA viruses in Cryphonectria parasitica, for example, lessen plant-pathogenic aggressiveness, supporting biocontrol.[186] Protist viruses, including those of amoebae and ciliates, exert evolutionary pressures in aquatic food webs. Giant viruses like mimiviruses target free-living amoebae, potentially reshaping bacterial predation.[187] These patterns underscore viruses' role in regulating populations across life's domains.[188]

Oncogenic Potential

Certain viruses, termed oncoviruses, can transform host cells and trigger tumorigenesis, accounting for 12-15% of human cancers worldwide per epidemiological links to specific malignancies.[189][190] This potential stems from disrupting cellular regulation, not direct viral proliferation, often with cofactors like chronic inflammation, immunosuppression, or genetic factors.[191] The International Agency for Research on Cancer (IARC) lists seven Group 1 carcinogens with sufficient human evidence: high-risk human papillomaviruses (HPVs), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), human T-lymphotropic virus type 1 (HTLV-1), Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), and Merkel cell polyomavirus (MCV).[192][193] High-risk HPVs (mainly types 16 and 18) cause about 5% of global cancers, including nearly all cervical cases, by integrating into the host genome and expressing E6 and E7 oncoproteins that inactivate p53 and Rb tumor suppressors, driving proliferation.[194] HBV and HCV drive over 75% of hepatocellular carcinomas; HBV integrates DNA to activate proto-oncogenes like c-Myc, while HCV's RNA genome causes chronic inflammation, oxidative stress, cirrhosis, and mutagenesis.[193] EBV associates with Burkitt's and Hodgkin's lymphomas plus nasopharyngeal carcinoma, using latent membrane protein LMP1 to mimic CD40 signaling and activate NF-κB, enabling B-cell immortalization and immune evasion.[194] HTLV-1 induces adult T-cell leukemia/lymphoma in 2-5% of carriers via Tax protein, which transactivates host genes and blocks DNA repair; KSHV fosters Kaposi's sarcoma through LANA stabilizing hypoxia-inducible factors and cyclin D; MCV integrates into Merkel cell carcinoma cells, with truncated T antigen disrupting Rb and p53.[193][195] Viral oncogenesis mechanisms overlap across diverse viruses, targeting shared host pathways. DNA viruses like HPV and HBV integrate genomes for insertional mutagenesis or antigen stimulation; RNA viruses like HCV and HTLV-1 provoke persistent inflammation through cytokines and reactive oxygen species, building mutations over time.[195] Viral proteins often hit apoptosis controls (e.g., EBV's Bcl-2 analogs), epigenetic regulators (e.g., KSHV's histone deacetylases), or cell cycle checkpoints; immunosuppression, as in HIV coinfection, heightens risk by hindering clearance.[196] Supporting data show HPV vaccination reducing cervical precancers by 90% in cohorts since 2006, and HBV programs halving liver cancer rates in Taiwan by 2010.[194] Progression to cancer varies; latency, host genetics (e.g., HLA alleles for EBV), and cofactors shape multifactorial outcomes.[191] Similar potentials occur in animals, like avian leukosis virus in chickens or mouse mammary tumor virus in rodents, though human surveillance dominates data.[195]

Prevention, Control, and Treatment

Host Defense Mechanisms

Host defense against viruses includes innate and adaptive immunity. The innate system offers rapid, non-specific protection via barriers and sensors, while the adaptive system provides antigen-specific, long-term immunity. These defenses counter viral tactics like host machinery hijacking and immune evasion, though viruses often counter with suppression or variation.[197][198] Physical barriers, such as intact skin, mucosa, and secretions containing lysozyme, initially block viruses by degrading envelopes or capsids. Breached barriers activate pattern recognition receptors (PRRs) that detect viral pathogen-associated molecular patterns (PAMPs), like double-stranded RNA or unmethylated CpG DNA. Cytosolic RIG-I-like receptors (RLRs) and endosomal Toll-like receptors (TLRs) then trigger interferon production.[199][200][198] Interferons induce antiviral states: Type I (IFN-α, IFN-β) upregulates interferon-stimulated genes (ISGs) in nearby cells, including protein kinase R (PKR) that blocks translation on dsRNA detection and 2'-5'-oligoadenylate synthetase (OAS) that activates RNase L to degrade RNA. Type III (IFN-λ) restricts replication at epithelia, and Type II (IFN-γ) boosts macrophage activation and MHC expression. Cell-intrinsic responses like autophagy, which degrades viral components, and apoptosis, which limits virus spread by sacrificing infected cells, provide further protection, despite viral inhibitions.[201][202][203] Natural killer (NK) cells target infected cells showing altered ligands or reduced MHC class I ("missing self"). They induce apoptosis via perforin and granzymes, and secrete IFN-γ to enhance responses. In humans, acute infections like cytomegalovirus can generate adaptive-like NK subsets with epigenetic specificity.[204][205] Adaptive immunity, initiated by dendritic cells presenting antigens, engages T and B cells. Cytotoxic CD8+ T cells lyse infected cells via MHC class I-presented peptides, using Fas-FasL or granule exocytosis. CD4+ helper T cells, recognizing MHC class II, secrete cytokines to activate macrophages and aid B cell differentiation. B cells generate neutralizing antibodies that block virion attachment or promote phagocytosis; memory cells ensure lasting immunity, as seen in varicella-zoster control after primary infection.[197][206][207] In non-vertebrates, RNA interference (RNAi) cleaves viral RNA: Dicer generates siRNAs from dsRNA, guiding Argonaute to target genomes. Prominent in plants and invertebrates, RNAi plays a minor role in mammals, overshadowed by interferons but active against viruses like influenza in interferon-deficient settings.[208][209][210]

Vaccine Development and Efficacy

Viral vaccines use strategies to induce protective immunity with minimal risk. Live-attenuated vaccines employ weakened strains mimicking natural infection, such as the 1960s measles-mumps-rubella (MMR) vaccine and Albert Sabin's 1961 oral polio vaccine (OPV).[211] Inactivated vaccines use killed particles, like Jonas Salk's 1955 inactivated polio vaccine (IPV) and seasonal influenza shots, which suit immunocompromised individuals but often need boosters due to dominant humoral immunity.[212] Subunit and recombinant vaccines focus on antigens, including hepatitis B surface antigen from yeast since 1986; newer approaches like viral vectors (e.g., adenovirus-based) and mRNA enable quick adaptation despite production challenges.[213] Key milestones include Edward Jenner's 1796 smallpox precursor and Max Theiler's 1937 yellow fever vaccine, the first lab-attenuated one via serial passage to curb virulence while retaining immunogenicity.[214] Efficacy measures, via randomized controlled trials, use vaccine effectiveness (VE) = (1 - [attack rate in vaccinated / attack rate in unvaccinated]) × 100% to assess symptomatic disease prevention.[215] Post-licensure observational studies gauge real-world effects on hospitalization or transmission, accounting for confounders like prior exposure or strain matching.[216] Stable viruses show high efficacy over 95%: smallpox vaccination eradicated the disease by 1980 through herd immunity at >80% coverage; measles vaccines cut cases >92% pre-1980, with two doses offering near-100% trial protection and saving 56 million lives from 2000-2021.[217] [218] Polio vaccines reduced U.S. cases >99% after 1955, with OPV providing mucosal immunity but rare reversion risks.[219] Influenza vaccines average 40-60% effectiveness yearly from antigenic mismatches, with 50% considered successful given viral evolution.[220] RNA viruses' high mutation rates (10^-3 to 10^-5 errors per nucleotide per cycle) drive antigenic drift and shift, complicating vaccines and favoring designs targeting conserved regions like hemagglutinin stalks.[221] [222] This causes waning protection in respiratory viruses, where escape mutants dodge antibodies; annual influenza updates often reduce efficacy against mismatches by up to 50%.[223] Pipelines use animal models (e.g., ferrets for influenza) and protection correlates like neutralizing antibody titers, though human translation falters for mucosal pathogens needing T-cell responses.[224] No vaccines exist for mutable viruses like HIV or norovirus, highlighting genetic instability's role in limiting durable immunity.[225]

Antiviral Therapies

Antiviral therapies include drugs that inhibit viral replication, entry, assembly, or release in host cells. They target virus-specific processes, sparing host functions, unlike vaccines or antibiotics.[226] Early examples emerged in the late 20th century: idoxuridine (1962) for herpes keratitis and acyclovir (1982) for herpes simplex virus as the first nucleoside analog.[227] Success requires prompt administration—often within 48 hours for acute infections like influenza—and combinations for chronic cases like HIV to suppress viral loads below detection.[228] Drug classes differ in action: nucleoside/nucleotide analogs like acyclovir mimic guanosine to terminate DNA synthesis in herpesviruses; neuraminidase inhibitors such as oseltamivir block influenza virion release; protease inhibitors disrupt HIV polyprotein maturation; RNA-dependent RNA polymerase inhibitors like remdesivir incorporate into RNA virus genomes, including SARS-CoV-2, to stop replication.[229] Entry inhibitors like enfuvirtide prevent HIV fusion, while integrase inhibitors block proviral DNA integration into host genomes.[230] These strategies leverage viral dependencies but limit spectra to narrow activity, given viruses' intracellular life and host mimicry.[231] For HIV, highly active antiretroviral therapy (HAART) since 1996 combines reverse transcriptase, protease, and integrase inhibitors, cutting mortality over 80% and suppressing virus in 90-95% of adherent patients, though adherence and toxicities remain issues.[227] Influenza drugs oseltamivir (1999) and zanamivir (1994) reduce symptoms by 1-2 days and complications if started early, but adamantanes are ineffective due to near-100% resistance by 2009.[232] Acyclovir or valacyclovir suppress herpes outbreaks in 70-80% of cases, yet resistance reaches 5-10% in immunocompromised patients via thymidine kinase mutations. For COVID-19, remdesivir (2020) lowers outpatient hospitalization risk by 87%, while nirmatrelvir-ritonavir (Paxlovid, 2021) reduces mortality and ICU admissions versus remdesivir alone.[233][234][235] Resistance stems from mutational escape, hastened by suboptimal dosing or monotherapy—e.g., 10-15% transmitted drug resistance in new HIV infections and 1-2% sporadic oseltamivir clusters in influenza.[236] Herpes resistance involves polymerase or kinase changes, requiring nephrotoxic alternatives like foscarnet in transplants.[237] Broader hurdles include cytotoxicity from host polymerase inhibition, poor bioavailability, and lack of pan-viral agents, spurring host-targeted options like interferons despite amplified side effects.[238] Pipeline innovations feature long-acting injectables, such as lenacapavir (approved June 2025) for twice-yearly HIV prevention with near-complete trial efficacy, addressing adherence.[239]

Non-Pharmaceutical Interventions

Non-pharmaceutical interventions (NPIs) include public health measures to curb viral transmission via behavioral, environmental, or policy changes, such as quarantine, social distancing, masking, and improved hygiene, without vaccines or drugs. These approaches interrupt infection chains by limiting contacts, especially for droplet- or aerosol-transmitted respiratory viruses. Used since ancient times, NPIs formalized during outbreaks like the 1918 influenza pandemic, where closures and distancing delayed peaks in some U.S. cities.[240] Evidence shows NPIs modestly lower incidence and reproduction numbers (R_t) for viruses like influenza and SARS-CoV-2, though efficacy varies with compliance, transmissibility, and timing. Randomized trials are scarce, and observational data faces confounders like voluntary changes.[241] Quarantine and isolation separate exposed or infected individuals, with roots in 14th-century plague control but adapted for viruses. Contact tracing and home quarantine contained SARS-CoV-1 in 2003, including over 1,500 Toronto cases. For COVID-19, targeted quarantine cut household secondary attacks by 50-80% in models, but broad lockdowns had mixed results. A 2024 meta-analysis of 24 studies found spring 2020 lockdowns reduced mortality by just 0.2% on average, with no clear link between stringency and per capita deaths. Critics argue public health accounts overlook pre-trends, substitution effects, and excess non-COVID deaths from reduced care.[242][243][244] Social distancing, via stay-at-home orders and limits, reduces contacts below R_0. Simulations for influenza showed workplace distancing cut cases by up to 30%, flattening curves. In early COVID-19 waves, distancing and closures dropped R_t by 20-50% per synthetic controls, but U.S. studies found no excess mortality decline after shelter orders, adjusting for baselines. Fatigue and evasion erode gains, with prolonged measures yielding minimal extra reductions, plus rises in mental health issues and economic harm.[245][246] Masking aims to block droplets, but RCTs for influenza-like illnesses show inconsistency; a 2008 household trial found surgical masks yielded no secondary infection reduction (relative risk 1.0). For SARS-CoV-2, reviews rate community masking low-to-moderate for symptoms, with observational links to 20-80% lower positivity odds indoors, yet trials like DANMASK-19 showed no infection protection. N95s exceed cloth in filtration, but adherence and use flaws limit impact; source control debates persist amid biases in pro-mask studies.[247][248][249] Handwashing and disinfection offer modest support; meta-analyses of six influenza RCTs found hand hygiene alone cut confirmed transmission by 16-21%, more with etiquette. Ventilation dilutes indoor aerosol loads, lowering attack rates in outbreaks. NPIs delay outbreaks and ease overload in high-R_0 pandemics but involve trade-offs; voluntary measures often sustain compliance better than mandates, avoiding coercion's harms.[250][251][252]

Applications and Technologies

Therapeutic Applications

Viruses serve as therapeutic agents via three main approaches: viral vectors for gene delivery, oncolytic viruses for tumor lysis, and bacteriophages for bacterial targeting. These exploit viruses' infection and replication capabilities, yet face challenges from immunogenicity, off-target effects, and inconsistent trial efficacy.[253][254] In gene therapy, modified viruses deliver functional genes to correct deficiencies. Adeno-associated virus (AAV) vectors gained approvals like Luxturna (voretigene neparvovec) in 2017 for retinal dystrophy, improving visual acuity in phase 3 trials.[255] Lentiviral vectors supported approvals for beta-thalassemia and sickle cell disease (Zynteglo in 2019, Casgevy in 2023), achieving transfusion independence in over 80% of patients. Early setbacks included a 1999 adenovirus trial death from cytokine storm and 2002-2004 retroviral-induced leukemias via insertional mutagenesis, prompting safer designs. By 2025, over 23 products using AAV and lentiviruses were approved globally, though non-integrating systems raise durability concerns.[256][257][258][259] Oncolytic virotherapy uses engineered viruses that selectively replicate in and destroy cancer cells, often boosting antitumor immunity. Talimogene laherparepvec (T-VEC), a modified herpes simplex virus, received FDA approval in 2015 for advanced melanoma, yielding 16% durable responses (versus 2% controls) and 23-month median survival in phase 3 trials.[260] Adenovirus-based ONCOS-102 showed safety and responses with checkpoint inhibitors in phase 1/2 trials for solid tumors. Meta-analyses indicate 20-30% objective responses in intermediate-to-advanced cancers, with survival gains in glioblastoma and head/neck squamous cell carcinoma, though results vary by tumor and immunity. Host antiviral responses limit systemic application, and trials show no broad survival benefits by 2025.[261][262] Bacteriophage therapy targets bacteria for lysis, countering antimicrobial resistance. Preclinical models demonstrate bacterial load reductions and survival improvements, such as 100% eradication in Pseudomonas aeruginosa pneumonia. Compassionate cases, like a 2017 Acinetobacter clearance in cystic fibrosis, underscore rapid effects. Phase 2 trials for Staphylococcus aureus infections achieved 70-80% resolution, but randomized data are scarce, resistance can arise, and approvals remain absent by 2025. Phage-antibiotic combinations enhance outcomes in vitro and in vivo.[263][264][265]

Research and Synthetic Viruses

Virological research employs techniques such as isolation in cell lines or embryonated eggs, electron microscopy, serological assays, polymerase chain reaction (PCR), quantitative reverse transcription PCR (qRT-PCR), and next-generation sequencing to study viral biology, amplify and characterize genomes, and examine replication cycles, host interactions, and pathogenesis in models like mice or ferrets.[266][267] Advances in synthetic biology enable de novo assembly of viral genomes from synthesized nucleic acids, supporting reverse genetics to identify functional elements and reconstruct extinct or unculturable viruses for vaccine development.[268] In 2002, Eckard Wimmer's team at Stony Brook University synthesized the 7.5 kilobase poliovirus genome by ligating overlapping oligonucleotides into full-length cDNA. Transcribed in vitro and transfected into cells, it produced infectious virions that replicated in culture and induced paralysis in transgenic mice expressing the human poliovirus receptor, mirroring wild-type behavior.[269][270] In 2017, David Evans and colleagues at the University of Alberta reconstructed horsepox virus—an orthopoxvirus related to extinct smallpox—from ten synthetic DNA fragments totaling 212 kilobases, ordered commercially. Assembly via recombination in yeast and Shope fibroma virus, followed by serial passage, yielded viable virus at about $100,000, showing potential for orthopoxvirus vaccine engineering.[271][272] Synthetic virology now includes RNA viruses such as influenza and coronaviruses, facilitating gain-of-function experiments and minimal genome studies, while demonstrating how routine molecular tools can recreate pathogens.[268]

Biotechnological Uses

Viruses function as versatile tools in biotechnology, especially via engineered viral vectors for targeted gene delivery into host cells.[253] These vectors leverage natural viral infectivity from types like adeno-associated viruses (AAV), lentiviruses, and adenoviruses, with replication genes removed to curb pathogenicity.[273] AAV enables long-term gene expression in non-dividing cells through episomal persistence, ideal for genetic disorders, while lentiviruses integrate transgenes into the host genome for stable expression in dividing cells, as in hematopoietic stem cell therapies.[274][254] Bacteriophages, which target bacteria, support phage therapy as an antibiotic alternative, selectively lysing pathogens without harming beneficial microbiota.[275] Engineered for greater specificity and efficacy, they combat multidrug-resistant infections from bacteria like Pseudomonas aeruginosa or Staphylococcus aureus.[276] Phage display technology screens peptide libraries to identify binding affinities for drug discovery and diagnostics.[277] In nanotechnology and synthetic biology, viruses serve as self-assembling scaffolds for nanomaterial fabrication. Plant viruses like tobacco mosaic virus (TMV) offer symmetrical protein capsids modifiable to template metal nanowires or encapsulate imaging agents.[278] These viral nanoparticles facilitate precise drug delivery and biosensors, benefiting from monodisperse sizes (10-300 nm), biocompatibility, and multifunctionality.[279] Similarly, M13 bacteriophages form conductive nanowires under electric fields, aiding electronics and environmental sensing.[280]

Weaponization Risks

Virus weaponization involves engineering or deploying them as biological agents to inflict mass casualties, disrupt societies, or attain strategic aims, capitalizing on transmissibility, aerosol stability, and genetic modifiability. Respiratory viruses like variola (smallpox) and filoviruses such as Marburg suit this due to high lethality and person-to-person spread, though challenges persist in preserving viability during dispersal and overcoming immunity.[281][282] In the Cold War, the Soviet Biopreparat program created offensive viral arms, stockpiling tons of weaponized smallpox for ICBMs and adapting Marburg for aerosol use, breaching the 1972 Biological Weapons Convention that bans development, production, and storage of such agents. A 1971 Aral Sea test dispersed smallpox, infecting workers and civilians, killing 10, and prompting urgent vaccination to halt spread. Spanning 50+ facilities and 50,000 staff, it also tested Venezuelan equine encephalitis virus for incapacitation. Conversely, the United States halted its efforts in 1969, eliminated stocks, and endorsed the BWC in 1975, following prior studies of agents like Q fever and tularemia.[283][282] No verified wartime deployment of viral bioweapons has occurred, yet post-treaty infractions expose verification shortfalls, with the BWC depending on voluntary confidence-building measures absent formal checks. Bioterrorism with viruses stays infrequent and ineffective; Aum Shinrikyo opted for bacteria. Potential dangers encompass non-state groups sourcing eradicated viruses from labs or assembling them through reverse genetics, as in the 2018 horsepox synthesis—a smallpox analog—for less than $100,000.[284][285][286] synthetic biology progress escalates hazards by permitting novel virus construction, amplified virulence, or immune dodging, fostering undetectable pathogens akin to natural epidemics. Dual-use studies, including gain-of-function boosting H5N1 avian influenza spread, erode distinctions between defense and offense, amid worries over lax security in resource-poor labs. Countermeasures feature export restrictions on dual-use gear and Australia Group pathogen rosters, but risks from rogue entities or post-1991 unsecured Soviet stocks endure as rare yet catastrophic threats.[287][286][288]

Controversies and Critical Perspectives

Gain-of-Function Research

Gain-of-function (GOF) research modifies pathogens like viruses in labs to enhance traits such as transmissibility, virulence, host range, or immune evasion.[289][290] Methods include genetic engineering, serial passaging in cultures or animals, and chimeric construction to explore evolution or countermeasures.[291] Proponents claim it anticipates pandemics and guides vaccines, but critics contend surveillance and modeling provide similar benefits without creating dangerous agents.[292][293] In 2011, Ron Fouchier at Erasmus Medical Center and Yoshihiro Kawaoka at the University of Wisconsin-Madison engineered airborne-transmissible avian influenza A(H5N1) in ferrets, models for human spread.[294] Fouchier used 10 passages with five mutations; Kawaoka created an H1N1 hybrid for droplet transmission.[295] NIH-funded, these raised biosafety and dual-use alarms, prompting NSABB to initially block publication details—released in 2012 after debate—and underscoring H5N1's limited mutations for mammal transmission.[294][295] The Obama administration paused federal GOF funding in 2014 for influenza, SARS, or MERS enhancements in mammals, citing poor risk-benefit analysis and incidents like CDC anthrax and H5N1 errors.[296][297] The pause excluded vaccine or basic virology work, ending in 2017 with HHS's P3CO framework: multidisciplinary reviews for enhanced potential pandemic pathogens (ePPPs), balancing merit against risks with strict biosafety.[298][299][300] GOF extended to coronaviruses via NIH grants to EcoHealth Alliance (2014-2019, $3.7 million total; $600,000 to Wuhan Institute of Virology for bat SARS-like viruses).[301] These inserted spike cleavage sites and passaged chimeras in humanized mice and bat cells, yielding more infectious strains per a 2015 Nature Medicine paper with WIV's Shi Zhengli.[302] NIH later found EcoHealth delayed reporting 10,000-fold mouse growth but ruled it non-P3CO GOF; critics argue it met broader enhancement criteria.[302][303] GOF risks encompass lab releases, as in 2003-2004 SARS escapes or 1977 H1N1 re-emergence from a vaccine trial, potentially igniting outbreaks despite BSL-3/4 containment.[289] Purported benefits—like mutation insights for surveillance or vaccines—lack proof of superiority over alternatives such as reverse genetics or modeling, amid incentives for high-risk funded work.[293][292] A 2023 GAO report highlighted HHS gaps in ePPP oversight, with virologist defenses potentially conflicted by funding ties.[304][305]

Laboratory Origin Hypotheses

The laboratory origin hypothesis proposes that SARS-CoV-2, the virus causing COVID-19, emerged from research at the Wuhan Institute of Virology (WIV) via an accidental leak during gain-of-function experiments on bat coronaviruses. This idea gained support from the WIV's work enhancing sarbecovirus transmissibility, partly funded by U.S. grants through EcoHealth Alliance, which involved serial passaging in humanized models to boost pathogenicity. Advocates note the lack of a confirmed intermediate host despite searches, plus the virus's initial detection in Wuhan—the site of leading bat coronavirus research—making a lab incident more straightforward than a natural spillover via undetected wildlife trade.[306][307][308] A central argument involves the furin cleavage site (FCS) in SARS-CoV-2's spike protein, a polybasic PRRA insertion absent in close relatives like RaTG13 (96.2% genomic identity). Though FCS appears in distant coronaviruses, its scarcity in SARS-like bat viruses, along with specific codon usage avoiding common lab CGG arginine codons, suggests to some engineering or lab adaptation over natural evolution. WIV experiments, such as chimeric viruses increasing mouse lethality, demonstrate relevant capabilities, though precursors are undisclosed.[309][302][310] Additional evidence includes WIV researchers' COVID-like illnesses in November 2019, before the official outbreak, and biosafety shortcomings like poor BSL-4 training. U.S. intelligence differs: the Department of Energy and FBI favor lab origin with moderate to low confidence, citing unreported illnesses and matching virus research. Critics of zoonosis highlight "Proximal Origin" authors' initial private support for lab escape, later shifted publicly amid NIH pressures from figures like Anthony Fauci to counter it, tied to funding interests. Sources rejecting lab origin, often academic or WHO-linked, show biases from limited Chinese data access and WIV ties, favoring geopolitical views over evidence. No definitive proof exists for either side, but lab viability endures given past virology leaks (e.g., 1977 H1N1) and untraced zoonotic sources despite surveillance. Calls persist for WIV database recovery and early sequences to resolve uncertainties.[308][306][311][312][313][314]

Debates on Viral Etiology

Critics argue that viruses have not been rigorously proven to cause disease, citing failures in isolation and adherence to causation criteria developed for bacteria. Robert Koch's 1884 postulates demand pure culture isolation, disease reproduction upon inoculation into healthy hosts, and re-isolation of the same agent—requirements unmet by viruses, which cannot replicate independently as obligate intracellular parasites.[315] In response, virologist Thomas Rivers proposed 1937 criteria focused on disease association, culture propagation, host pathology induction, immunological specificity, and re-isolation. Detractors claim these too falter, as cell cultures often include fetal bovine serum and antibiotics, where cytopathic effects (CPE) might stem from starvation or toxicity rather than viruses. Stefan Lanka's experiments showed CPE in uninoculated controls, implying artifacts in isolation claims.[316][317] Lanka's 2011 challenge offered €100,000 for a single publication proving measles virus existence and direct causation via six criteria. David Bardens submitted papers, prompting a 2015 district court order for payment, overturned in 2016 by the Federal Court of Justice for relying on multiple studies instead of one source.[318] Skeptics view this as affirming unproven etiology, noting no literature achieves contaminant-free isolation or transmission in healthy subjects. Terrain theory proponents further argue that "viral" particles are endogenous exosomes or debris from metabolic toxicity and internal imbalance, not external invaders of a healthy terrain, as shown by varied disease outcomes among exposed individuals.[319] In contrast, mainstream virology holds that Rivers' criteria, plus molecular updates like Fredricks and Relman's sequence-based postulates, are met for many viruses through genomic detection in diseased tissues, specific antibody responses, and animal model fulfillments. SARS-CoV-2, for example, satisfied these via patient isolation, serial propagation, and disease induction in ferrets and hamsters with matching re-isolation.[320] Epidemiological data, such as outbreak declines post-vaccination tied to antibody titers, bolster causality, despite ethical limits on human challenges.[321] Debates continue, with dissent often dismissed as pseudoscience, potentially overlooking flaws in virological foundations since the 1930s.[322]

Critiques of Public Health Narratives

Critiques of public health narratives on viral outbreaks, especially the COVID-19 pandemic, focus on the limited empirical effectiveness of interventions like lockdowns and mask mandates, alongside suppression of dissenting views. A meta-analysis of early 2020 lockdowns in Europe and the United States estimated a 0.2% average reduction in COVID-19 mortality, indicating modest impact relative to socioeconomic costs.[323] Another meta-analysis found small effects from spring 2020 lockdowns, with initial messaging overstating benefits of "flattening the curve" to avert healthcare overload while ignoring harms like delayed non-COVID treatments.[244] U.S. excess mortality from 2020-2023 exceeded 1 million in 2020-2021 alone—surpassing reported COVID deaths—due partly to disrupted care, contradicting claims attributing all excess deaths to the virus.[324][325] Mask mandates drew criticism for depending on observational data over randomized controlled trials (RCTs). Meta-analyses indicated modest transmission reductions, but high-quality RCTs yielded inconsistent results, such as an 18% risk reduction for wearers in one study but no community-level benefits in others.[326][327] On February 5, 2020, Anthony Fauci stated masks were unnecessary for the public to preserve supplies for healthcare workers, yet later mandates deemed them essential amid evolving evidence that overlooked physiological burdens like added respiratory effort.[328][329] Public campaigns portrayed these measures as unequivocally life-saving, though systematic reviews emphasized context-dependent benefits often offset by compliance issues, mental health declines, and economic fallout inadequately considered in policy.[330] Critics highlight institutional suppression of alternative views, including biases in agencies like the NIH and government-influenced platforms. The Great Barrington Declaration, authored by epidemiologists Jay Bhattacharya, Sunetra Gupta, and Martin Kulldorff in October 2020, proposed focused protection for vulnerable groups over broad lockdowns to curb wider harms; it collected over 15,000 signatures from scientists and clinicians but encountered censorship, such as Google downranking and social media deplatforming of signatories.[331][332] U.S. government contacts with tech companies prompted indirect censorship, as affirmed in federal court, undermining trust in narratives that rejected such evidence-based arguments on age-stratified risks.[333] Early NIH dismissal of the lab-leak hypothesis as a "conspiracy theory"—including Fauci's role in shaping "Proximal Origin"—ignored private admissions of its viability, favoring institutional alignment over debate, as congressional probes revealed.[311][313][334][335] Mandatory vaccination policies, promoted for herd immunity, faced reproach for downplaying waning efficacy and overstating absolute risk reduction, which diminished future compliance.[336] Fauci's denial of U.S. funding for gain-of-function research at the Wuhan Institute of Virology—despite NIH grants to EcoHealth Alliance for bat coronavirus studies—exposed inconsistencies, as emails showed unpublicized lab safety worries.[337] These patterns suggest public health narratives favored consensus over first-principles evidence on transmission and trade-offs, eroding credibility through perceived overreach.[338]

References

User Avatar
No comments yet.